

Farzanna S, Haffizulla, MD FACP FAMWA

12555 Orange Drive, Suite 257

Davie, FL 33330

Twitter: [@BusyMomMD](#)

www.HousecallsMD.us

www.BusyMomMD.com

drfhaffizulla1@gmail.com or

fhaffizull@nova.edu

Primary Specialty & Work Experience:

2017-present

- ❖ Assistant Dean for Community & Global Health, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)
- ❖ Assistant Professor of Medicine, NSU Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)

2008-present

Board Certified Internal Medicine Private Practice

- ❖ Farzanna S, Haffizulla MD/JFDOC P.L.
12555 Orange Drive, Suite 257, Davie, FL,
General Internal Medicine & Women's Health Hybrid Concierge Practice
www.HousecallsMD.us

2003-2008

Board Certified Internal Medicine

- ❖ General Internal Medicine & Women's Health Medical Associates of Tamarac
Tamarac, FL
- ❖ <http://meditam.net/>

Residency Education:

2000-2003

Internal Medicine Residency
Cleveland Clinic Florida
Weston, FL

Cleveland Clinic Foundation
Cleveland, OH

Graduate Medical Education:

1996-2000

University of Miami
Miami, FL

Medical Doctor (M.D.)
University of Miami Miller School of Medicine

Undergraduate Education

1991-1995

University of Central Florida, Orlando, FL
Summa cum laude & University Honors
Bachelor of Science, Molecular Biology & Microbiology

Academic Appointments

2017-present

- ❖ Assistant Dean for Community & Global Health, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)
- ❖ Assistant Professor of Medicine, NSU Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD)

2004-present

- ❖ Voluntary Assistant Professor of Medicine University of Miami Miller School of Medicine

2008- present

- ❖ Affiliate Clinical Asst, Professor in the Charles E, Schmidt College of Biomedical Science at Florida Atlantic University
- ❖ American Heritage Pre-med Tract Science, Adjunct Faculty: Honors Organic Chemistry

Licensure

2003- present (active)

Florida Medical License ME 86693

2011-2013 (inactive)

Alabama Medical License - 30903

American Board of Internal Medicine (ABIM) Certification

04-16-13 to 04-2023 (current)

Recertification, ABIM Maintenance of Certification Exam

08-19-2003 to 08-19-2013

Diplomat, American Board of Internal Medicine

Professional Organizational Membership

- ❖ Founding Member, AMWA Leadership Council
- ❖ Member, National Association of Professional Women
- ❖ Lifetime Member, Fellow of the American Medical Women's Association
 - Founder, Chair Emeritus, Preventive Medicine Task Force
 - Founder, Chair, Fellowship Program
 - Past Chair, Governance
 - Past Chair, Public Relations Committee
 - Past Co-Chair Program Committee
 - Past Executive Chair, Fundraising Committee
 - Past Member, Global and International Outreach Committee
 - Past Member, Membership Committee
 - Past Member, Finance Committee
 - Past Member, Executive Committee
 - Past President, President-elect, Immediate Past President, Board of Directors
 - Member, Past President's Council
 - Member, Awards Committee
 - Founding member, AMWA Leadership Council
- ❖ Lifetime Member, Indian Physicians of South Florida
- ❖ Member, Broward County Medical Association
- ❖ Member and Fellow, American College of Physicians
 - FL Chapter, 2016 [Annual Scientific Meeting Program Committee member](#), Key Largo, Florida
 - Co-Chair, [Women in Medicine Networking Breakfast](#)
- ❖ Diplomat, American Board of Internal Medicine
- ❖ Designated Institutional Representative, American Association of Medical Colleges, Group on Women in Medicine and Science (GWIMS)
- ❖ Member, International Women's Leadership Association
- ❖ Member, Medical Women's International Association
- ❖ Member, Alumni Association, University of Central Florida
- ❖ Member, Alumni Association, Cleveland Clinic Foundation
- ❖ Member, Alumni Association, University of Miami Miller School of Medicine

Service at Nova Southeastern University's College of Allopathic Medicine (NSU MD):

Committees:

- ❖ Founding team member, NSU MD
- ❖ Member, Dean's Cabinet
- ❖ Founding member, Data Sciences Committee
- ❖ Member, Office of Medical Education Leadership Committee
- ❖ Strategic Planning Committee Member (SPC)
- ❖ Member, Faculty Search and Screen Committee
- ❖ Member, Curriculum Committee
- ❖ Member, Diversity Committee
- ❖ Member, Office of Community Engagement Committee
- ❖ International Affairs Advisory Council
- ❖ Member, Admissions Committee
- ❖ Co-chair, Admissions Committee
- ❖ Member, Faculty Council
- ❖ Founding Chair, Group on Women in Medicine and Science
- ❖ Chair, Diversity Committee
- ❖ Member, NSU MD Wellness Committee
- ❖ Member, Educational Program Innovations (NSU-wide)

Appointed Leadership Roles:

2018- present

- ❖ NSU MD Designated Institutional Representative, American Association of Medical Colleges Group on Women in Medicine and Science (GWIMS)

2015 to present

- ❖ 2015 Honorary Board of Educators- National Academy of Future Physicians and Medical Scientists
- ❖ National Delegate, Florida Representative for Vision 2020: Drexel College of Medicine's Institute for Women's Health and Leadership

Faculty and Research Advisor/Mentor Roles:

2018- present

- ❖ Member, Community Coalition Sub-committee (NSU MD- Strategic Planning Committee)
- ❖ Faculty Advisor, NSU MD American Medical Women's Association
- ❖ NSU MD Service-Learning Faculty Lead and Mentor
 - Women in Distress Organization Educational Campaign on Sexually Transmitted Infection Prevention– Students: Jacob Oster, Mashtura Hasan, Haley Ehrlich, Iliza Minaya, Sydney Stillman and Neha Bapatla
 - PitchSafe Concussion Prevention Educational Campaign– Students: Chase Labiste, Evan McElroy and Sotiris Chaniotakis
- ❖ NSU MD Student Research Mentor

- Labiste C, McElroy E, Duong N, Chaniotakis S, Haffizulla FS PitchSafe: Assessment of Concussion Knowledge and Attitudes Amongst Parents of Youth Baseball Players - IRB approved, NSU MD RISE Conference, September 13, 2019
- William C, Haffizulla FS Factors contributing to Avoidable Emergency Department Visits in Broward County – IRB approved, NSU MD RISE Conference, September 13, 2019
- ❖ NSU Razor’s Edge Scholars Mentor (in collaboration with NSU’s Fischler School of Education)

Teaching Responsibilities:

2018 to present

- ❖ Faculty Lecturer, NSU MD Class of 2023 Professional Immersion Session: Community and Population Health: Opportunities for Innovation, Engagement and Leadership, August 8, 2019
- ❖ Faculty Lecturer, NSU MD Class of 2022 Professional Immersion Session: Community and Population Health: Community Engagement and Population Health, August 7, 2018
- ❖ NSU MD Physician Facilitator, Practice of Medicine 1
- ❖ NSU MD Physician Facilitator, Practice of Medicine 2
- ❖ NSU MD Physician Facilitator, Practice of Medicine 3
- ❖ NSU MD Physician Facilitator, Clinical Reasoning Course
- ❖ NSU MD Physician Facilitator, Diagnostic Medicine Course

2008 to present

- ❖ Course Director, Faculty; Pre-Medical Program, American Heritage School; Honors Organic Chemistry

Community Engagement, Service and Leadership

2020

- ❖ Invited NSU Leadership, Florida’s Children First - Broward Advocates for Children, Broward Center for the Performing Arts, February 20, 2020
- ❖ Invited member, American Medical Women’s Association Leadership Council
- ❖ Invited member, American Heart Association Health Literacy and Cultural Competency Committee

2019 to present

- ❖ Board member, March of Dimes
- ❖ Founding committee member for the International Woman in Medicine Educational Advancement Program, ACP-AMWA Collaboration

2019

- ❖ Invited NSU Leadership, Mathew Forbes Romer Foundation – Celebration of Gene Therapy Awards Gala, The Seagate Country Club, Florida, March 16, 2019
- ❖ Invited NSU Leadership, American Heart Association’s Broward Heart Ball, The Ritz Carlton, Florida, April 6, 2019
- ❖ Board member participant, March for Babies, NSU main campus, May 4, 2019

- ❖ Board member, 2019 Broward March of Babies - Awards & Recognition Celebration, Pembroke Pines, Florida, June 28, 2019
- ❖ Board member, March of Dimes – Hispanic Women of Distinction Luncheon, Signature Grand, Florida, August 23, 2019
- ❖ Board member participant/team captain, American Diabetes Association Step Out Walk 2019, Huizenga Park, October 19, 2019
- ❖ Board Member participant, Broward County Medical Association Annual Dinner, Westin Resort, Florida, December 7, 2019

2018 to present

- ❖ Board member, American Diabetes Association-South Florida
- ❖ American Medical Women’s Association Strategic Planning Committee member- Appointed, Fall 2018
- ❖ American Medical Women’s Association Awards Committee, Appointed Fall 2018
- ❖ Health Care Industry Steering Committee, Greater Hollywood Chamber of Commerce
- ❖ Honorary Executive Board Member, Indian Physicians of South Florida
- ❖ Expert Physician Contributor, Sharecare.com

2018

- ❖ Board member participant, American Diabetes Association Step Out Walk 2018, Huizenga Park, October 2018
- ❖ Member participant, Annual NSU/Broward County “Out of the Darkness” walk, NSU Fellows Ways, November 11, 2018
- ❖ Member participant, BCMA 92nd Presidential Inauguration & Dinner, Sixty-Six Hotel & Marina, Florida, November 17, 2018

2017 to present

- ❖ Member, Florida Department of Health-Broward County; Fitness and Nutrition Task Force
- ❖ Member, Florida Department of Health- Broward County; Outreach Planning Group
- ❖ Member, Health Care Access Committee, Broward Regional Health Planning Council

2016 to present

- ❖ Chief Scientific Officer, Haven Home Health

2016

- ❖ Special Invitation and Participant, Office of Women’s Health, First Opioid Use, Abuse, and Misuse in Women Summit, September 2016

2015-2016

- ❖ Immediate Past President, American Medical Women’s Association
- ❖ Medical Director, Haven Home Health

2015 to present

- ❖ On- camera Host/Medical Correspondent for Elsevier's PracticeUpdate Oncology and Rheumatology Series

2015

- ❖ AMWA President and Presiding Executive Chair, Centennial National Meeting of the American Medical Women's Association, Palmer House Hilton, Chicago, IL, April 23-26, 2015
- ❖ Special Invitation and Participant, First United State of Women Summit, White House, Washington D.C., June 14, 2015

2014-15

- ❖ President, American Medical Women's Association
- ❖ Medical Advisory Panel as AMWA President, You and Your Family national magazine
- ❖ AMWA Fellowship program founder; co-chair of Fellowship taskforce

2013-2014

- ❖ President-elect, American Medical Women's Association (AMWA)
- ❖ Preventive Medicine Task Force founder/chair of AMWA – in support of the Surgeon General's National Prevention Strategy
- ❖ Executive Chair of Fundraising-American Medical Women's Association
- ❖ AMWA Governance Committee member
- ❖ Co-Chair of National AMWA's Public Relations Committee
- ❖ Membership and Marketing Committee of National AMWA
- ❖ Global Outreach Committee of National AMWA
- ❖ AMWA Finance Committee member
- ❖ AMWA mentor

2014

- ❖ Speaker, Event Moderator and Executive Chair: First annual AMWA/AHS Family Health and Wellness Educational Symposium, American Heritage School in Plantation, January 11, 2014,

2013-present

- ❖ National Health Show Host, Anchor & Clinical Editor for Mission Critical Health
- ❖ National Delegate- Florida Representative, Vision 2020 National Program; Drexel's Institute for Women's Health and Leadership
- ❖ Physician Ambassador for the Broward County Department of Health

2012-2013

- ❖ Founding President, South Florida Branch, American Medical Women's Association

2012

- ❖ Executive Chair - [First Annual Women's Wellness Health Fair](#), South Florida Branch, American Medical Women's Association, December 2012

2011-2012

- ❖ Medical Director and Advisory Board Member, Advocate Home Care Services

2011 to present

- ❖ Physician Scientist board member, Advarra's Center for Institutional Review Board Intelligence

2008 to 2009

- ❖ Physician expert contributor for All Points Bulletin Radio, "The Doctor is In"
www.bsolive.org

2008 to present

- ❖ Concierge Internal Medicine Practice Owner and Founder, HouseCallsMD/JFDOC PL
- ❖ Founder and owner, BusyMomMD.com

2005 to 2008

- ❖ Clinical Preceptor, University of Miami Miller School of Medicine

Patents/Inventions:

- ❖ Co-inventor, Patient e-Navigation System – Health GPS (2018, in provisional patent status)
- ❖ Founder, Co-inventor, **Mentoring Minorities in Medicine** ©2019 App for iOS and Android (**M3 Program**©2019); September 2019, patent pending

Research Projects and Grant Funding:

- ❖ Investigator, REACH Registry: The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design, 2006
REACH is a worldwide registry run by a multidisciplinary group of investigators intended to illuminate cardiovascular risk factors in stable outpatients. **Please see the Appendix A** for publications arising from the REACH registry.
- ❖ Principal Investigator, **Caribbean Diaspora Healthy Nutrition Outreach Project (CDHNOP)** – IRB approved, June 2018 - ongoing
 - NSU Quality of Life Grant Funded, May 2018: \$15, 000
 - GiveCampus and City of North Miami – 2019 funding: \$21, 158
 - Frederick A DeLuca Foundation Grant Funded, November 15, 2019: \$25, 000
- ❖ Principal Investigator, **Assessment of Burnout in Women Physicians, an International Survey** – IRB approved, July 2019 - ongoing
 - Data collection complete
 - Current stage: Data analysis and results
- ❖ Principal Investigator, **Social Determinants of Prostate Cancer Risk and Mortality in the**

Caribbean Diaspora of South Florida, applied October 2019

- Grant submitted for \$1,435,724,67 (not funded): James and Esther King Biomedical Research Program

- ❖ Co-Investigator, ***Longitudinal Curriculum for Substance Use Disorders*** – Funding Granted by DCF; 10/2019; \$250,000

- ❖ Founder, Co-Inventor, NSU MD Diversity Pipeline/ **Mentoring Minorities in Medicine**® 2019 iOS and Android app

- ❖ American Medical Women's Association Regional Meeting funding received, October 2019: \$14,140

Published Books:

- ❖ Farzanna Haffizulla MD FACP, ***Lead With Your Heart – A Doctor's Rx for Personal and Professional Success*** July 2014; Dandelion Books

- ❖ Farzanna S, Haffizulla, M,D,, ***Harmony of the Spheres - Career, Family, and Community: A Working Mom's Lessons of Love, Strength, and Balance*** September 2011, (available on BusyMomMD.com, Amazon and Kindle)

- ❖ Book reviews on ***Harmony of the Spheres: Career, Family and Community*** by:
 - Palm Beach Gardens Lifestyle magazine, Vol 4, no 2, p 34, Positive Parenting under Pressure by Lynn Kreps
 - AMWA Connections, Summer 2012, Book Review by Theresa Rohr- Kirchgraber, MD: Harmony of the Spheres: A Working Mom's Lessons of Love, Strength & Balance, Farzanna Sherene Haffizulla, MD, p 7

Publications:

Articles published in numerous national magazines and publications, please see <http://busymommd.com/media.html> for more information,

National:

- ❖ **Haffizulla FS**, *Improve your Family's IQ: Ways to make education come naturally*, About Families, March 2012, p20-21

- ❖ **Haffizulla FS**, *Conquering a Sick Day*, Eastern Pennsylvania Business Journal, Jan 9th, 2012 Vol 23, no,1 p5;15

- ❖ **Haffizulla FS**, *Styles of Mothering: What type of Mother are you anyway?* Austin Family,

August 2012, p14-15

- ❖ **Haffizulla FS**, *Styles of Mothering: What type of Mother are you anyway?* e Bella, July 2012, p 24,25,
- ❖ **Haffizulla FS**, *Mindset for Success*, The Pulse Legal Publication Sun, March 11th, 2012, Vol 17, No, 169 p4
- ❖ **Haffizulla FS**, *Mindset for Success*, SQE Professional, Spring 2012, Issue 81, p 26-27;
- ❖ **Haffizulla FS**, *Mindset for Success*, Synovus Bank, 2012, p5
- ❖ **Haffizulla FS**, *Mindset for Success*, Home Business-Special Success Issue, August 2012, p12
- ❖ **Haffizulla FS**, *Mindset for Success*, AKWA Magazine, Aug/Sept 2012, Vol 26, no, 2, p33-34
- ❖ **Haffizulla FS**, *Conquering a Sick Day*, Canadian Manager-a Publication of the Canadian Institute of management, Vol 37, no 1, Spring 2012, p16-17; OTC Magazine, February 2013, p 46
- ❖ **Haffizulla FS**, *Mindset for Success*, Franchise Canada, July/August 2012 p 38-39

Global

- ❖ **Haffizulla FS**, [Creating a Work Life Balance Plan](#), AMWA-American Medical Women's Association, June 11, 2012
- ❖ **Haffizulla FS**, [Negotiating a Flexible Work Arrangement as a Physician](#), (2 versions written, one for the business audience and another for the parenting demographic), American Medical Women's Association, June 19, 2012

Peer Reviewed Journals:

- ❖ **Haffizulla FS**, Ramoutar A, Eason A, Hardigan P, *Caribbean Diaspora Healthy Nutrition Outreach Project (CDHNOP): A Qualitative and Quantitative Approach to Caribbean Health*. Annals of Global Health. 2020; 86(1): 11, 1-12. DOI: <https://doi.org/10.5334/aogh.2657>
- ❖ Haffizulla JM, **Haffizulla FS**, Haffizulla KD, Beck, LH. *A Dangerous Encounter with Naphthalene*. Hospital Physician 2002, Vol, 38, Number 11, pp, 61-64

Submitted for Publication in 2020, The Permanente Journal. Publication Decision: Pending

- ❖ **Haffizulla FS** et al, *Assessment of Burnout in Women Physician, An International Survey*

Poster Presentations:

- ❖ **Haffizulla, FS** et al, Caribbean Diaspora Healthy Nutrition Outreach Project: A Quantitative and Qualitative Approach to Caribbean Health; 105th Annual meeting of the American Medical Women's Association (AMWA), Indianapolis, Indiana; March 26th, 2020
- ❖ Labiste C, McElroy E, Duong N, Chaniotakis S, **Haffizulla FS**, *PitchSafe: Assessment of Concussion Knowledge and Attitudes Amongst Parents of Youth Baseball Players* - IRB approved, NSU MD RISE Conference, September 13, 2019
- ❖ William C, **Haffizulla FS** *Factors contributing to Avoidable Emergency Department Visits in Broward County* – IRB approved, NSU MD RISE Conference, September 13, 2019
- ❖ Haffizulla JM, **Haffizulla FS**, *A Dangerous Encounter with Mothballs, ACP-ASIM Regional meeting The Florida Internist 2001 & 2002*

Invited Media, Interviews & Features:

- ❖ Featured Internal Medicine Physician, American College of Physicians: [*My Kind of Medicine: Real Lives of Practicing Internists: Farzanna S, Haffizulla MD FACP*](#), October 2014
- ❖ Featured in Practicelink Magazine, [*Finding Your Work/Life Balance*](#), Winter 2014, P 30-39
- ❖ Featured in HerLife magazine, Health and Wellness Edition, January 2014, p 25
- ❖ Featured, [*Cleveland Clinic Foundation Alumni Connections*](#), Issue 1, Front Page, 2014
- ❖ National Society of High School Scholars, [*Parent Leader Interview: Why is NSHSS worth it?*](#) November 18, 2014
- ❖ Featured in Caribbean Today Newspaper, [*Trinidadian Doctor Heads the American Medical Women's Association in its 100th year*](#), April 2015
- ❖ Featured in Caribbean Today, [*Caribbean Doctor Blazes Unique Path In Medicine*](#), 2015
- ❖ Medscape Interview, [*Female Physicians on Creating Alternative Career Paths*](#), April 2015

- ❖ Medscape Interview, [**Female Doctors' Pay Still Falls Short-Why?**](#) May 2015
- ❖ Featured Interview, Frontline Medical Communications and Clinical Endocrinology News, [**Work/Life Balance: Can women physicians have it all? Absolutely, say AMWA past president.**](#) June 2, 2015
- ❖ Featured Interview with Frontline Medical Communications and OBGYN News on Work/Life Balance:
[http://www.obgynnews.com/?id=11146&tx_ttnews\[tt_news\]=407337&cHash=3e1ed85d0e474ff2f6804f3174de842d](http://www.obgynnews.com/?id=11146&tx_ttnews[tt_news]=407337&cHash=3e1ed85d0e474ff2f6804f3174de842d)
- ❖ Featured in [**Top 10 Caribbean-born doctors in the US**](#), News America, April 14, 2016
- ❖ Front Cover Feature with editorial spread, Trinidad Guardian Newspaper, **Repping Health and T and T**, October 2, 2016

Quotes:

- ❖ Physician Quote in the Chicago Tribune, **Marital Support Key to Managing Work Stress**, By Cindy Krischer Goodman, McClatchy-Tribune
- ❖ Expert Quote, PreCheck Blog, [**Flexible Work, Golden Opportunities in Healthcare**](#), September 28, 2016
- ❖ Quote on HIV for Broward County Department of Health, [**Busy Doctors Embrace Routine HIV Testing**](#), CBS local, Miami, May 9, 2017
- ❖ Physician Quote, Tampa Bay Times, [**Feeling allergy symptoms? Blame Hurricane Irma, some doctors say**](#), Written by Justine Griffin, October 5, 2017

Blogs:

- ❖ Miami Herald's Blog, [**Mommy doctor gives Work/Life Balance tips**](#) by Cindy Goodman, February 14, 2012
- ❖ WomenMD Resources guest blog, [**President of the American Medical Women's Association \(AMWA\) Speaks Out on Her Agenda for the Coming Year**](#) by Linda Brodsky, June 27, 2013
- ❖ Featured Guest on the #CareerCrush Bossed Up Series hosted by CEO, Emilie Aries, July 26, 2016
- ❖ Expert Contributor, New England Journal of Medicine Resident 360 Discussion Forum, Powered by Medstro, Women Physicians: Lower Pay for Better Outcomes? February

13th, 2017

Foreword:

- ❖ Haffizulla FS, Foreword as AMWA President and **Work, Balance, Strive, [You and Your Family](#)**, Fall 2014, p 8

Radio:

- ❖ The Doctor is in radio show segments done at ALL Points Bulletin with Sheriff Al Lamberti/Commander Calderin, Aired on WWNN AM radio 1470 on Sundays 2pm EST, For more show info go to: <http://busymommd.com/media.html> or www.bsolive.org
- ❖ Special Radio show guest on Pearls of Health AM1230
- ❖ Featured Guest on FindaTopDoc Blog Talk Radio, **[Empowering Women in Life and Health](#)**, March 18, 2014

Television, Videos:

- ❖ TV Host, Medical Correspondent, Contributing Physician Content Editor for **Elsevier's PracticeUpdate Series** with a special focus in Oncology and Rheumatology, Provided clinical editing and **hosted over 618 videos**. All videos are accessible using this link: <https://www.practiceupdate.com/author/farzanna-haffizulla/1760>

Video interviews take place at national and international medical conferences such as:
American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology- Genitourinary (ASCO-GU)
Society of Neuro-Oncology (SNO)
San Antonio Breast Cancer Conference (SABCS)
American College of Rheumatology (ACR)

PracticeUpdate offers an array of professional research, information, and education resources in a single online destination, with a breadth and depth of content that is unrivaled,

All site content is organized by specialties and areas of interest, enabling practitioners to instantly and easily access the latest news, scientific updates, and expert opinion pertaining to their specialty, PracticeUpdate's mission is to connect healthcare professionals with news and information that matters most for patient care, Videos and transcripts are published in Elsevier's Oncology Centers of Excellence and in Elsevier's print journal: Practice Update Conference Series

Public Service Message Videos/Op-ed:

- ❖ Pensacola News Journal, [*Small Talks with Teens About Drinking*](#), April 10, 2014
- ❖ Public Service Message Series as host of Mission Critical Health:
 - [*Mental Health America: Mind Your Health Series*](#) (Parts 1-4)
 - **Mind your Health Interview: Improving Access to Counseling**
 - [*Responsible Alcohol consumption*](#)
 - [*Pre-operative Hygiene Compliance Prevention of Bed Ulcers*](#)
 - [*Health Care Associated Infections and the Anti-microbial properties of Copper the Impact of Diet on Chronic Illness*](#)
 - [*Adverse Health Effects of Marijuana Use Tips for Staying Healthy During Flu Season*](#)
- ❖ 103rd annual meeting of the American Medical Women's Association, U, S, Bone and Joint Initiative: [*Preventing Arthritis due to Sports Injury*](#), Philadelphia, PA, Fall 2018

Invited Speaking Engagements

Local

- ❖ Graduation Keynote Speaker, Allied Health new Training Program: Cambridge College of Healthcare and Technology, 2006
- ❖ Keynote Speaker, ***Work/Life balance***, Florida Atlantic University Medical School, 2013
- ❖ Keynote Speaker and Moderator, ***Northwest Regional Medical Center Women's wellness/AMWA Event***, June 2013
- ❖ Speaker, [*First Annual AMWA/AHS Family Health and Wellness Educational Symposium*](#), American Heritage School – Plantation, Florida, January 11, 2014
- ❖ Keynote Speaker, ***Work/Life Balance: Women in Medicine Gala***, Cleveland Clinic-Women Professional Staff Association, September 2nd, 2015
- ❖ Women in Medicine Panel Speaker, University of Miami Miller School of Medicine, November 2015
- ❖ Keynote Speaker and Book signing, Florida International University School of Medicine, December 2015

- ❖ Women in Medicine Panel Speaker, University of Miami Miller School of Medicine, October 2016
- ❖ Keynote Speaker, Breast Cancer Survivors event at Neiman Marcus, October 2016
- ❖ Keynote Speaker and Award Recipient, **9th Annual Medical Admissions Symposium**- University of Central Florida College of Medicine
- ❖ Keynote Speaker, **Precision Medicine Initiative: Roundtable Discussion on Comprehensive Health Services and Improving Patient Outcomes**, Fort Lauderdale, Florida, December 2016
- ❖ Colloquium Keynote Speaker, **NSU International Women's Day**, March 27th, 2018
- ❖ Keynote Speaker, **Future of Medicine: Visions on the Horizon**, Walgreens Regional Office, Miramar, FL, April 2018
- ❖ Panel Speaker, **The Future of Healthcare: An Executive Outlook**, Bisnow's State of South Florida Healthcare, Westin, FL, July 17th, 2018
- ❖ Speaker and invited participant, Council of Florida Medical School Deans, **Translational Wellness**, Orlando, Florida, August 2018
- ❖ Speaker, NSU Ambassador Board, **National Trends in Science, Medicine and Health Care: NSU Poised to Lead Change**, September 13, 2018
- ❖ Speaker and invited participant, **Vision 2020 – Increasing Women's Civic Engagement**, Marriott Mia Biscayne Bay, Florida, September 29, 2018
- ❖ Keynote speaker, **American Medical Women's Association Region 4 (Southeast US): Raise Your Voice in Medicine: Creating Actionable Strategies for Change**, Florida State University College of Medicine, October 6, 2018
- ❖ Keynote speaker, **4th Annual 'A Road for the Cure' Children's Cancer Foundation**, Marriott Heron Bay, October 20, 2018
- ❖ Keynote speaker, **Masjid Al Hijrah Sisters of the Jamaat Event**, October 27, 2018
- ❖ Panelist and Speaker, **NSU MD Make an Impact in Law and Medicine**, NSU, December 11, 2018
- ❖ Speaker, Broward Regional Health Planning Council's Health Care Access Committee, **Caribbean Health Initiatives: Statement of Need and Mission**, February 25, 2019
- ❖ Welcome speaker, **South Florida Executive Roundtable – Women's Leadership**

Roundtable Breakfast Panel, NSU Florida, March 7, 2019

- ❖ Speaker, **American Diabetes Association: Partners to Stop Diabetes Networking Breakfast**, May 21, 2019
- ❖ Speaker, **NSU MD Diabetes Care Health Summit: Unmet Needs in Care Continuum**, June 9, 2018
- ❖ Opening Keynote Speaker, **[South Florida Hospital & Health Care Association's Annual Health Summit](#); *Health Care Revolution: The Age of Disruption and Innovation***; Signature Grand, Davie, FL, June 14, 2019
- ❖ Speaker, Moffitt Cancer Center Conference with NSU Health Professions Leadership: **Minorities and Underserved Populations**, NSU, June 21, 2019
- ❖ Speaker, AMSA National Primary Care Week, **Addressing the Primary Care Physician Shortage: Re-imagining Medical Training and Practice**, Nova Southeastern University – Morris Auditorium, October 11, 2019
- ❖ Welcome Speaker, **5th Annual 'A Road for the Cure' Children's Cancer Foundation**, Coral Springs Marriott, October 19, 2019
- ❖ Moderator, NSU's Lunch and Learn Oncology and Nutrition Community Education, **Avoiding Cancer through Healthy Nutrition**, October 23, 2019
- ❖ Speaker, Health Panel, **City of Lauderhill Resiliency Symposium, Family and Community Health**, October 27, 2019
- ❖ Speaker, **2019 Step Out Walk Awards Reception**, Bahama Breeze, November 6, 2019
- ❖ Speaker & demonstrator, Lauderhill Business Brunch: Business Revolution-Vision 2025, **How impactful exercise or stretch could be to physical and mental performance**, Lauderhill Performing Arts Center, January 16, 2020
- ❖ Welcome speaker, **Juvenile Diabetes Foundation – Progress to Type None**, NSU Florida, January 30, 2020
- ❖ Speaker, **Healthy Mothers, Healthy Babies Coalition of Broward County - 28th Mother's Day VIP Honoree Reception**, Signature Grand, February 11th, 2020
- ❖ Speaker, **14th Annual SFHHA Healthcare Summit – VIP Dinner**, Signature Grand, February 12th, 2020

- ❖ Speaker, ***South Florida Executive Roundtable – Women’s Leadership Roundtable Breakfast Panel***, NSU Florida, February 25, 2020
- ❖ Speaker, ***NSU Welcome Address***, Cotilla Gallery – Alvin Sherman Library; March for Babies Kickoff event, March of Dimes, March 4, 2020
- ❖ Keynote Speaker, ***University of South Florida American Medical Women’s Association Chapter***, March 21, 2020

National

- ❖ Chicago Salon Lecture, ***Lead With Your Heart – A Doctor’s Rx for Personal and Professional Success***, August 9, 2014
- ❖ Keynote Speaker, ***Lead With Your Heart – A Doctor’s Rx for Personal and Professional Success***, Women Professional Staff Association – Cleveland Clinic Foundation, Ohio, August 21, 2014
- ❖ Medicine Panel Speaker, ***7th Annual Women in Leadership Conference***, Yale School of Law, February 7, 2015
- ❖ Guest Speaker, Yale School of Medicine Branch event, February 6, 2015
- ❖ Thought Leader, National Institutes of Health consensus summit: ***Increasing Diversity in Science, Medicine & Research***
- ❖ Speaker, Women Heart Coalition’s Opinion Leaders Workshop: ***Improving Doctor-Patient Communication***, Washington D. C. April 2015
- ❖ Co-Host, Speaker and Special Guest, ***American College of Physician’s Women Physicians Networking Luncheon***, Key West, Florida, May 1, 2015
- ❖ Leader and Participant, ***Women’s Cardiovascular Health – Women Heart***, First National Policy & Science Summit, October 2015
- ❖ Speaker and Moderator, Fort Lauderdale’s iGiant initiative on Medical Devices - ***Impact of Gender and Sex on Innovation and Novel Technologies***, YOLO’s Las Olas, Florida, December 2015
- ❖ Florida National Delegate, ***Institute of Women’s Health and Leadership 6th National Congress: Paths to Shared Leadership***, Marriot Biscayne Bay, September 2018

- ❖ Speaker, ***Doctors for America- AMWA Past Presidents national call to action***, October 8, 2018
- ❖ Plenary Speaker, ***3rd Annual Women in Medicine and Science Professional Development Conference***, Southern Illinois University, June 19, 2020

International

- ❖ Florida's Medicare Quality Improvement Organization (FMQAI) Physician Champion and National Teleconference Speaker, 2008
- ❖ Speaker, ***[Second Global Women's Leadership Summit: World Medical Tourism/Global Health Care Congress](#)***, Washington D. C. September 20, 2014
- ❖ United Nations Speaker, Commission on The Status of Women Parallel event with MWIA, ***Strength in Synergy: An Empowered Global Approach to Leadership, Medicine and Science***, New York, March 2015
- ❖ Panelist and Moderator, ***Work, Balance, Strive***, Centennial Meeting of the American Medical Women's Association, Chicago, Illinois, April 23, 2015
- ❖ World Medical Tourism/Global Healthcare Congress expert speaker, ***Harmonize Your Life: Achieving Work-Life Balance***, September 29, 2015
<http://www.medicaltourismcongress.com/medical-agenda/wellness-healthy-mind-healthy-body-maintaining-a-work-life-balance/>
- ❖ Speaker, 2017 Emerge Americas international conference, ***Marriage of Medicine & Technology - Preserving the Human Element in an Era of Rising Technology***, June 12, 2017
- ❖ Plenary Speaker, ***Women's Economic Forum***, New Delhi, India, May 2018
- ❖ Congress Speaker and Session co-leader, Medical Women's International Association Centennial, ***Physician Burnout/Work life Balance: Juggle, Balance, Thrive: Re-Defining Work-Life Balance***; New York, July 26, 2019
- ❖ Speaker, Medical Women's International Association Executive Meeting, ***Making Part-Time Work- Policies and Practices Affecting Maternity Leave***; New York, July 27th, 2019
- ❖ Opening Speaker, ***American Medical Women's Association Southeast Regional Meeting***, Hosted by NSU's MD and DO Medical Schools on the NSU campus, October 5, 2019

NSU MD Lectures:

- ❖ Speaker, NSU MD Lunch and Learn Series, ***Inter-Professional Collaboration: A Population Health Perspective***, March 2018
- ❖ Planning Committee Lead and Speaker Panel Moderator, ***NSU MD Diabetes Care Health Summit: From Volume to Value***, June 9, 2018
- ❖ Lecturer, NSU MD Charter Class Professional Immersion Session: ***Community Engagement & Population Health***, August 7, 2018
- ❖ Speaker, NSU MD Lunch and Learn Series, ***Achieving the Triple Aim in Health Care: Community Collaboration Strategies***, December 19, 2018
- ❖ Lecturer, NSU MD Class of 2022 Professional Immersion Session: ***Community and Population Health: Community Engagement and Population Health***, August 7, 2018
- ❖ Lecturer, NSU MD Class of 2023 Professional Immersion Session: ***Community and Population Health: Opportunities for Innovation, Engagement and Leadership***, August 8, 2019

Interests & Activities:

1991-1995

University of Central Florida

Orlando, FL

- ❖ Co-founder & President of Student for Student organization
- ❖ Honors & Scholars Club member
- ❖ Director of Education, Secretary, Pre-Med AMSA
- ❖ Newsletter director, Pre-Med AMSA
- ❖ Student Government Eligibility Appeals Committee member
- ❖ Phi Eta Sigma Fundraising Director
- ❖ Health Outreach & Public Relations, Pre-Med AMSA
- ❖ Caribbean Club member

1996-2000

University of Miami Miller School of Medicine

Miami, FL

- ❖ Board of Directors member, Florida Academy of Family Physicians
- ❖ President, Family Practice Student Organization

- ❖ Student Director, Florida Academy of Family Physicians
- ❖ Student Advisor, Family Practice Student Organization
- ❖ Co-chair, Membership Committee, University of Miami Medical Women
- ❖ Medical Ethics Lecture co-organizer
- ❖ National Primary Care Forum, co-organizer/participant
- ❖ Membership Liaison for the American Academy of Family Physicians
- ❖ Chiron Society Member
- ❖ University of Miami Medical Women panelist
- ❖ Exec, Committee member, fundraising co-chair, Florida Keys Health Fair
- ❖ Volunteer at the Overtown Minorities Health Fair
- ❖ Student volunteer at Miami Hope Health and South Shore Community Clinics
- ❖ Graduation Committee member
- ❖ Mentorship Committee member, University of Miami Medical Women
- ❖ American Medical Student Association
- ❖ Medical Education Committee Member
- ❖ National Congress of Family Practice Residents/National Council of Student Members participant 1998
- ❖ American Medical Women's Association member

2000-2003: Cleveland Clinic Florida Weston, FL

- ❖ Residency Training Committee
- ❖ ACP/ASIM Florida Local Council of Associates, CCF representative
- ❖ Editorial Board, The Florida Internist
- ❖ Publications Committee, ACP/ASIM Local Council Member
- ❖ ACP/ASIM Medical Jeopardy Representative, Cleveland Clinic Florida

Established Student Scholarships:

- ❖ \$2,000 annual [Haffizulla Family Scholarship](#) donated to AMWA students in support of disease prevention, Two \$1,000 annual scholarships will be awarded at AMWA annual meeting
- ❖ \$25,000: Drs, Jason and Farzanna Haffizulla Endowment Fund in support of NSU MD under-represented minority students

Awards:

- ❖ Selected as a woman of outstanding leadership in Healthcare by The International Women's Leadership Association: May 2012
- ❖ Selected as a Woman of Outstanding Leadership by the International Women's Leadership Association: May 2014
- ❖ A Leading Physician of the World Award, The International Association of Healthcare Professionals
- ❖ Most Outstanding Undergraduate 1995, Dept. of Molecular Biology & Microbiology
- ❖ Omicron Delta Kappa National Leadership Honors Society
- ❖ Golden Key National Honors Society
- ❖ Phi Kappa Phi National Honors Society
- ❖ Honors Program Medallion Award
- ❖ Founders' Day Honors and Recognition
- ❖ Who's Who Among Students in American Universities and Colleges
- ❖ First Place UCF (University of central Florida) Public Speaking Festival
- ❖ Charles Milligan Scholarship
- ❖ H. Trevor Colbourn Scholarship
- ❖ UCF Honors Program Book Scholar
- ❖ Top 1% College of Health & Public Affairs
- ❖ Certificate of Achievement for being in top 5% at UCF

- ❖ FMQAI Culturally Competent Physician Champion Award (Aug 2008)
- ❖ Quality First Award from Florida Healthcare Coalition (August 2008)
- ❖ Stanford Who's Who
- ❖ Selected for Faces of AMWA recognition <https://www.amwa-doc.org/faces/farzanna-sherene-haffizulla-md/>
- ❖ Selected as a woman of Outstanding leadership by the International Women's Leadership Assn: March 2014
- ❖ Direct Fellowship with the American College of Physicians
- ❖ Volunteerism and Community Service award from the Florida Chapter of the American College of Physicians- August 2014
- ❖ Honorable Service Awards American Medical Women's Association 2015
 - Chair/Founder: Preventive Medicine Task Force
 - Co-Chair/Founder: AMWA Fellowship Program
 - Lead Chair: Centennial Program Committee
- ❖ Inaugural Fellowship Awardee: American Medical Women's Association- April 2015
- ❖ Certificate of Recognition and Appreciation from the National Academy of Future Physicians and Medical Scientists-May 2015
- ❖ Appreciation Award from the Cleveland Clinic's Women Professional Staff Association- Award given in recognition of keynote speech on work/life balance at the Women in Medicine Gala – September 2, 2015,
- ❖ Keynote Speaker award: 9th Annual Medical Admissions Symposium- University of Central Florida College of Medicine – February 2016
- ❖ Presidential Recognition Award – American Medical Women's Association 2016
- ❖ Bertha Van Hoosen award_– American Medical Women's Association, March 2017
- ❖ Global Award The Most Outstanding Advocate for Integrated Community Care in the World in 2017 London, England; Global Awards Over 50's Housing and Healthcare
- ❖ Excellence in Community Service, Nova Southeastern University's Celebration of Excellence 2018
- ❖ Woman of the Decade in Community Leadership Awardee, 2018; Women's Economic Forum

and the All Ladies League, New Delhi, India

- ❖ Quality of Life Grant (\$15,000) for Caribbean Diaspora Healthy Nutrition Outreach Project, first grant approved/awarded for NSU MD Faculty, May 15, 2018
- ❖ [American College of Physicians Impact feature](#), September 2018
- ❖ AL-HIKMAT Annual Award Ceremony: Young, successful professionals 2018
- ❖ [Leading Woman in Medicine](#) and Health Care, Florida Medical Business, October 2018
- ❖ AMWA Doctors “Women in Medicine” Month Highlight, September 2019
- ❖ Selected, Mother of the Year Award; Healthy Mothers, Healthy Babies, May 2020

Appendix A

❖ Publications arising from the REACH registry:

- van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; **REACH Registry investigators**, Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria, *Eur Heart J*, 2017 Nov 14;38(43):3211-3218, doi: 10.1093/eurheartj/ehx102, PubMed PMID: 28369481,
- Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG; **REACH Registry Investigators**, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk, *Heart*, 2017 Sep;103(17):1339-1346, doi: 10.1136/heartjnl-2016-310705, Epub 2017 Mar 11, PubMed PMID: 28285267,
- Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Reid CM, Baumgartner I, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G; **REACH Registry Investigators**, Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry, *Clin Cardiol*, 2017 Sep;40(9):710-718, doi: 10.1002/clc.22721, Epub 2017 May 18, PubMed PMID: 28520087,
- Bavry AA, Elgendy IY, Elbez Y, Mahmoud AN, Sorbets E, Steg PG, Bhatt DL; **REACH Registry Investigators**, Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events, *Clin Cardiol*, 2017 Sep;40(9):732-739, doi: 10.1002/clc.22724, Epub 2017 May 18, PubMed PMID: 28520215,
- Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G; **REACH Registry Investigators**, Residual Ischemic Risk and Its Determinants in Patients with Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry, *Clin Cardiol*, 2016 Nov;39(11):670-677, doi: 10.1002/clc.22583, Epub 2016 Sep 2, PubMed PMID: 27588731,
- Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica BM; **REACH Registry Investigators**, Angina and Future Cardiovascular Events in Stable Patients with Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry, *J Am Heart Assoc*, 2016 Sep 28;5(10), pii: e004080, doi: 10.1161/JAHA.116.004080, PubMed PMID: 27680665; PubMed Central PMCID: PMC5121505,
- Selvaraj S, Steg PG, Elbez Y, Sorbets E, Feldman LJ, Eagle KA, Ohman EM, Blacher J, Bhatt DL; REACH Registry Investigators, Pulse Pressure and Risk for Cardiovascular

Events in Patients With Atherothrombosis: From the REACH Registry, *J Am Coll Cardiol*, 2016 Feb 2;67(4):392-403, doi: 10,1016/j.jacc,2015,10,084, PubMed PMID: 26821627,

- Hansel B, Roussel R, Elbez Y, Marre M, Krempf M, Ikeda Y, Eagle KA, Elisaf M, Bhatt DL, Steg PG; **REACH Registry Investigators**, Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis, *Eur Heart J*, 2015 Oct 21;36(40):2716-28, doi: 10,1093/eurheartj/ehv347, Epub 2015 Aug 4, PubMed PMID: 26242715,
- Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; **REACH Registry Investigators**, Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry, *Circulation*, 2015 Sep 8;132(10):923-31, doi: 10,1161/CIRCULATIONAHA,114,014796, Epub 2015 Jul 7, PubMed PMID: 26152709,
- Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL; **REACH Registry Investigators**, Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry, *Eur Heart J*, 2014 Nov 1;35(41):2864-72, doi: 10,1093/eurheartj/ehu080, Epub 2014 Feb 28, PubMed PMID: 24585266; PubMed Central PMCID: PMC4216432,
- Ademi Z, Liew D, Gorelik A, Bohensky M, Zomer E, Hollingsworth B, Steg G, Bhatt DL, Reid CM; **REACH Registry investigators**, Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data, *Int J Cardiol*, 2014 Jul 15;175(1):72-7, doi: 10,1016/j.ijcard,2014,04,230, Epub 2014 Apr 28, PubMed PMID: 24816526,
- Kohli P, Steg PG, Cannon CP, Smith SC Jr, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL; **REACH Registry Investigators**, NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease, *Am J Med*, 2014 Jan;127(1):53-60,e1, doi: 10,1016/j.amjmed,2013,08,017, Epub 2013 Nov 23, PubMed PMID: 24280110,
- Ruff CT, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, Hoffman EB, Ohman EM, Eagle KA, Lip GY, Goto S; **REACH Registry Investigators**, Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry, *Int J Cardiol*, 2014 Jan 1;170(3):413-8, doi: 10,1016/j.ijcard,2013,11,030, Epub 2013 Nov 25, PubMed PMID: 24321327,
- Ademi Z, Huq MM, Liew D, Steg PG, Bhatt DL, Nelson M, Reid CM; **REACH Registry investigators**, The impact of lost therapeutic benefit (LTB) in high-risk hypertensive

patients: 2-year follow-up data from the Australian REACH registry, *Cardiovasc Ther*, 2013 Dec;31(6):370-6, doi: 10,1111/1755-5922,12034, PubMed PMID: 23582191,

- Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, Ohman EM, Umez-Eronini AA, Hoffman E, Bhatt DL; **REACH Registry Investigators**, Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry, *Clin Cardiol*, 2013 Dec;36(12):721-7, doi: 10,1002/clc,22217, Epub 2013 Oct 25, PubMed PMID: 24166484,
- Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL; **REACH Registry Investigators**, Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis, *Eur Heart J*, 2013 Apr;34(16):1204-14, doi: 10,1093/eurheartj/ehs368, Epub 2012 Nov 9, PubMed PMID: 23144048,
- Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, Cayla G, Chastre T, Baumgartner I, Röther J, Zeymer U, Bhatt DL, Steg G, Montalescot G; **REACH Registry Investigators**, Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors, *Int J Cardiol*, 2013 Mar 10;163(3):266-271, doi: 10,1016/j.ijcard,2011,06,015, Epub 2011 Jun 29, PubMed PMID: 21719126,
- Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM; **REACH Registry Investigators**, Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort, *Cardiovasc Ther*, 2013 Feb;31(1):45-52, doi: 10,1111/j,1755-5922,2011,00291,x, Epub 2011 Jul 1, PubMed PMID: 21884025,
- Sirimarco G, Amarenco P, Labreuche J, Touboul PJ, Alberts M, Goto S, Rother J, Mas JL, Bhatt DL, Steg PG; **REACH Registry Investigators**, Carotid atherosclerosis and risk of subsequent coronary event in outpatients with atherothrombosis, *Stroke*, 2013 Feb;44(2):373-9, doi: 10,1161/STROKEAHA,112,673129, Epub 2013 Jan 10, PubMed PMID: 23306325,
- Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; **REACH Registry Investigators**, β -Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease, *JAMA*, 2012 Oct 3;308(13):1340-9, doi: 10,1001/jama,2012,12559, PubMed PMID: 23032550,
- Duval S, Massaro JM, Jaff MR, Boden WE, Alberts MJ, Califf RM, Eagle KA, D'Agostino RB Sr, Pedley A, Fonarow GC, Murabito JM, Steg PG, Bhatt DL, Hirsch AT; **REACH Registry Investigators**, An evidence-based score to detect prevalent peripheral artery

- disease (PAD), *Vasc Med*, 2012 Oct;17(5):342-51, doi: 10,1177/1358863X12445102, Epub 2012 Jun 17, PubMed PMID: 22711750,
- Venkitachalam L, Wang K, Porath A, Corbalan R, Hirsch AT, Cohen DJ, Smith SC Jr, Ohman EM, Steg PG, Bhatt DL, Magnuson EA; **REACH Registry Investigators**, Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance, *Circulation*, 2012 Apr 17;125(15):1858-69, doi: 10,1161/CIRCULATIONAHA,111,064378, Epub 2012 Apr 9, PubMed PMID: 22492667,
 - Dallongeville J, Bhatt DL, Steg PH, Ravaud P, Wilson PW, Eagle KA, Goto S, Mas JL, Montalescot G; **REACH Registry Investigators**, Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry, *Eur J Prev Cardiol*, 2012 Apr;19(2):241-9, doi: 10,1177/1741826710394305, Epub 2011 Feb 25, PubMed PMID: 21450609,
 - Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, Smeath A, De Looze F, Steg PG, Bhatt DL, Liew D; **REACH Registry Investigators**, Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis, *Med J Aust*, 2012 Feb 20;196(3):193-7, PubMed PMID: 22339526,
 - Smolderen KG, Wang K, de Povourville G, Brüggjenjürgen B, Röther J, Zeymer U, Parhofer KG, Steg PG, Bhatt DL, Magnuson EA; **REACH Registry Investigators**, Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease, *Eur J Vasc Endovasc Surg*, 2012 Feb;43(2):198-207, doi: 10,1016/j.ejvs,2011,09,016, Epub 2011 Oct 15, PubMed PMID: 22001145,
 - Ademi Z, Reid CM, Hollingsworth B, Stoelwinder J, Steg PG, Bhatt DL, Vale M, Liew D; **Reach Registry Investigators**, Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry, *Clin Ther*, 2011 Oct;33(10):1456-65, doi: 10,1016/j.clinthera,2011,08,004, Epub 2011 Oct 7, PubMed PMID: 21982384,
 - Keo HH, Baumgartner I, Hirsch AT, Duval S, Steg PG, Pasquet B, Bhatt DL, Roether J; **REACH Registry Investigators**, Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease, *Vasc Med*, 2011 Oct;16(5):323-30, doi: 10,1177/1358863X11419997, Epub 2011 Sep 9, PubMed PMID: 21908682,
 - Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, Liao CS, Wilson PW,

- Salette G, Smith SC, Steg PG; **REACH Registry Investigators**, Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry, *Mayo Clin Proc*, 2011 Oct;86(10):960-7, doi: 10,4065/mcp,2011,0010, PubMed PMID: 21964173; PubMed Central PMCID: PMC3184025,
- Alberts MJ, Bhatt DL, Smith SC Jr, Röther J, Goto S, Hirsch AT, Steg PG; **REACH Registry Investigators**, Risk factors and outcomes for patients with vascular disease and serious bleeding events, *Heart*, 2011 Sep;97(18):1507-12, doi: 10,1136/hrt,2010,221788, Epub 2011 Jun 29, PubMed PMID: 21715441,
 - Morrell J, Zeymer U, Baumgartner I, Limbourg T, Röther J, Bhatt DL, Steg PG; **REACH Registry Investigators**, Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe, *Eur J Cardiovasc Prev Rehabil*, 2011 Apr;18(2):270-7, doi: 10,1097/HJR,0b013e32833cca34, PubMed PMID: 20606595,
 - Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Röther J, Bhatt DL, Steg PG; **REACH Registry Investigators**, Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe, *Heart*, 2011 Apr;97(8):660-7, doi: 10,1136/hrt,2010,213710, Epub 2011 Feb 25, PubMed PMID: 21357372,
 - Chiu JF, Bell AD, Herman RJ, Hill MD, Stewart JA, Cohen EA, Liau CS, Steg PG, Bhatt DL; **REACH Registry Investigators**, Cardiovascular risk profiles and outcomes of Chinese living inside and outside China, *Eur J Cardiovasc Prev Rehabil*, 2010 Dec;17(6):668-75, doi: 10,1097/HJR,0b013e328339eb74, PubMed PMID: 20431393,
 - Smolderen KG, Bell A, Lei Y, Cohen EA, Steg PG, Bhatt DL, Mahoney EM; **REACH Registry Investigators**, One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry, *Can J Cardiol*, 2010 Oct;26(8):297-305, PubMed PMID: 20931098; PubMed Central PMCID: PMC2954538,
 - Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG; **REACH Registry Investigators**, Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis, *JAMA*, 2010 Sep 22;304(12):1350-7, doi: 10,1001/jama,2010,1322, Epub 2010 Aug 30, PubMed PMID: 20805624,
 - Bangalore S, Bhatt DL, Röther J, Alberts MJ, Thornton J, Wolski K, Goto S, Hirsch AT,

- Smith SC, Aichner FT, Topakian R, Cannon CP, Steg PG; **REACH Registry Investigators**, Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry, *Circulation*, 2010 Sep 14;122(11):1091-100, doi: 10.1161/CIRCULATIONAHA.109.933341, Epub 2010 Aug 30, PubMed PMID: 20805431,
- Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB Sr, Steg PG, Bhatt DL; **REACH Registry Investigators**, Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis, *Crit Pathw Cardiol*, 2010 Sep;9(3):116-25, doi: 10.1097/HPC.0b013e3181e7f93e, PubMed PMID: 20802264,
 - Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, Röther J, Bhatt DL, Steg PG; **REACH Registry Investigators**, Influence of polyvascular disease on cardiovascular event rates, Insights from the REACH Registry, *Vasc Med*, 2010 Aug;15(4):259-65, doi: 10.1177/1358863X10373299, PubMed PMID: 20724374,
 - Mechtouff L, Touzé E, Steg PG, Ohman EM, Goto S, Hirsch AT, Röther J, Aichner FT, Weimar C, Bhatt DL, Alberts MJ, Mas JL; **REACH Registry Investigators**, Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease, *J Intern Med*, 2010 Jun;267(6):621-33, doi: 10.1111/j.1365-2796.2009.02198.x, Epub 2009 Nov 25, PubMed PMID: 20210837,
 - Wang TD, Goto S, Bhatt DL, Steg PG, Chan JC, Richard AJ, Liau CS; **REACH Registry Investigators**, Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis: results from the REduction of Atherothrombosis for Continued Health (REACH) Registry, *Metabolism*, 2010 Mar;59(3):400-8, doi: 10.1016/j.metabol.2009.08.009, Epub 2009 Oct 2, PubMed PMID: 19800641,
 - Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Röther J, Goto S, Pasquet B, Wilson PW; **Reach Registry Investigators**, Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry), *Am J Cardiol*, 2010 Mar 1;105(5):667-71, doi: 10.1016/j.amjcard.2009.10.048, PubMed PMID: 20185014,
 - Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DL; **REACH Registry Investigators**, Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry), *Am J Cardiol*, 2010 Feb 15;105(4):445-52, doi: 10.1016/j.amjcard.2009.10.014, Epub 2010 Jan 5, PubMed PMID: 20152237,

- Parhofer KG, Zeymer U, Stark RG, Binz C, Schwertfeger M, Bhatt DL, Steg PG, Röther J; **REACH Registry Investigators**, In Germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis--results from the REACH registry, *Exp Clin Endocrinol Diabetes*, 2010 Jan;118(1):51-6, doi: 10,1055/s-0029-1225648, Epub 2009 Oct 15, PubMed PMID: 19834877,
- Ademi Z, Liew D, Hollingsworth B, Wolfe R, Steg GP, Bhatt DL, Reid CM; **REACH Registry Investigators**, The economic implications of treating atherothrombotic disease in Australia, from the government perspective, *Clin Ther*, 2010 Jan;32(1):119-32; discussion 106-7, doi: 10,1016/j,clinthera,2010,01,009, PubMed PMID: 20171418,
- Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM; **REACH Registry Investigators**, Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry, *Am J Cardiovasc Drugs*, 2010;10(2):85-94, doi: 10,2165/11530670-000000000-00000, PubMed PMID: 20334445,
- Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC Jr, Wilson PW, Watson KE, Steg PG; **REACH Registry Investigators**, Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry, *Am Heart J*, 2009 Dec;158(6):1038-45, doi: 10,1016/j,ahj,2009,09,014, PubMed PMID: 19958873,
- Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson M, Soman A, Steg G, Bhatt DL, Reid C; **REACH registry investigators**, Drug treatment and cost of cardiovascular disease in Australia, *Cardiovasc Ther*, 2009 Fall;27(3):164-72, doi: 10,1111/j,1755-5922,2009,00090,x, PubMed PMID: 19689615,
- Aichner FT, Topakian R, Alberts MJ, Bhatt DL, Haring HP, Hill MD, Montalescot G, Goto S, Touzé E, Mas JL, Steg PG, Röther J; **REACH Registry Investigators**, High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH Registry, *Eur J Neurol*, 2009 Aug;16(8):902-8, doi: 10,1111/j,1468-1331,2009,02614,x, Epub 2009 Mar 31, PubMed PMID: 19473362,
- Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, Bhatt DL; **REACH Registry Investigators**, Renal function, atherothrombosis extent, and outcomes in high-risk patients, *Am Heart J*, 2009 Jul;158(1):141-148,e1, doi: 10,1016/j,ahj,2009,05,011, PubMed PMID: 19540404,

- Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Röther J, Steg PG, Hirsch AT; **REACH Registry Investigators**, Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry, *Atherosclerosis*, 2009 Jun;204(2):e86-92, doi: 10.1016/j.atherosclerosis,2008,10,023, Epub 2008 Oct 31, PubMed PMID: 19054514,
- Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Steg PG, Cannon CP, Brennan DM, Bhatt DL; **REACH Registry Investigators**, Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry, *Crit Pathw Cardiol*, 2009 Jun;8(2):91-7, doi: 10.1097/HPC,0b013e3181a84613, PubMed PMID: 19417637,
- Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Röther J, Wilson PW, Richard AJ, Eagle KA, Ohman EM; **REACH Registry Investigators**, Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry, *Eur Heart J*, 2008 Dec;29(24):3052-60, doi: 10.1093/eurheartj/ehn478, Epub 2008 Nov 7, PubMed PMID: 18996953; PubMed Central PMCID: PMC2638656,
- Goto S, Bhatt DL, Röther J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, Wilson PW, Corbalán R, Aichner F, Steg PG; **REACH Registry Investigators**, Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis, *Am Heart J*, 2008 Nov;156(5):855-63, 863,e2, doi: 10.1016/j.ahj,2008,06,029, Epub 2008 Sep 23, PubMed PMID: 19061698,
- Baumgartner I, Hirsch AT, Abola MT, Cacoub PP, Poldermans D, Steg PG, Creager MA, Bhatt DL; **REACH Registry investigators**, Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry, *J Vasc Surg*, 2008 Oct;48(4):808-14, doi: 10.1016/j.jvs,2008,05,026, Epub 2008 Jul 17, PubMed PMID: 18639426,
- Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, Mosse F, Jackson JD, Steg PG, Bhatt DL; **REACH Registry Investigators**, One-year costs in patients with a history of or at risk for atherothrombosis in the United States, *Circ Cardiovasc Qual Outcomes*, 2008 Sep;1(1):38-45, doi: 10.1161/CIRCOUTCOMES,108,775247, PubMed PMID: 20031786,
- Röther J, Alberts MJ, Touzé E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, Wilson PW, Steg PG; **REACH Registry Investigators**, Risk factor profile and management of

cerebrovascular patients in the REACH Registry, *Cerebrovasc Dis*, 2008;25(4):366-74, doi: 10.1159/000120687, Epub 2008 Mar 13, PubMed PMID: 18337635,

- Sabouret P, Cacoub P, Dallongeville J, Krempf M, Mas JL, Pinel JF, Priollet P, Steg G, Taminau D, Montalescot G; **REACH Registry Investigators**, REACH: international prospective observational registry in patients at risk of atherothrombotic events, Results for the French arm at baseline and one year, *Arch Cardiovasc Dis*, 2008 Feb;101(2):81-8, PubMed PMID: 18398391,
- Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, Yamada N, Matsumoto M, Origasa H, Bhatt DL, Steg PG, Ikeda Y; **REACH Registry Investigators**, Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan, *Circ J*, 2007 Jul;71(7):995-1003, PubMed PMID: 17587702,
- Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP; **REACH Registry Investigators**, Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry), *Am J Cardiol*, 2007 May 1;99(9):1212-5, Epub 2007 Mar 16, PubMed PMID: 17478144,
- Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; **REACH Registry Investigators**, One-year cardiovascular event rates in outpatients with atherothrombosis, *JAMA*, 2007 Mar 21;297(11):1197-206, PubMed PMID: 17374814,
- Touzé E, Mas JL, Röther J, Goto S, Hirsch AT, Ikeda Y, Liau CS, Ohman EM, Richard AJ, Wilson PW, Steg PG, Bhatt DL; **REACH Registry Investigators**, Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry, *Stroke*, 2006 Dec;37(12):2880-5, Epub 2006 Oct 26, PubMed PMID: 17068303,
- Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW; **REACH Registry Investigators**, The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design, *Am Heart J*, 2006 Apr;151(4):786,e1-10, PubMed PMID: 16569533,
- Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; **REACH Registry Investigators**, International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with

atherothrombosis, JAMA, 2006 Jan 11;295(2):180-9, PubMed PMID: 16403930,

Appendix B

Recent Contributions to Practice Update:

1. [Importance of Exercise Among Breast Cancer Patients](#)
2. [Intravenous and Oral NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting Among Breast Cancer Patients](#)
3. [Advancing Cancer Care in the Caribbean](#)
4. [JAK2 and PD-L1 in 9p24 Amplified Breast Cancer](#)
5. [Future Directions in the Adjuvant Treatment of HER2+ Breast Cancer](#)
6. [Matching Tumor Tissue DNA Sequencing With Circulating Tumor DNA in Clinical Practice](#)
7. [Immunotherapy for Glioblastoma](#)
8. [Overcoming the Blood–Brain Barrier in the Management of Brain Tumors](#)
9. [Inequities in Breast Cancer Treatment in Sub-Saharan Africa](#)
10. [Novel Therapeutic Targets in the Management of Breast Cancer](#)
11. [Biosimilars for HER2-Targeted Antibodies](#)
12. [Novel Approaches in the Management of Opioid Addiction](#)
13. [Changing Paradigms in the Management of Brain Metastases](#)
14. [Trilaciclib Plus Chemotherapy for Metastatic TNBC](#)
15. [The Immune Landscape of Residual TNBC After Neoadjuvant Chemotherapy](#)
16. [Immunologic Correlates of Long-Term Outcomes in TNBC](#)
17. [Proton Radiotherapy for Low-Grade Glioma](#)
18. [Financial Toxicity in Metastatic Breast Cancer](#)
19. [Oral Paclitaxel for Patients With Recurrent or Metastatic Breast Cancer](#)
20. [Palliative Care in the Management of Patients With Brain Cancer](#)
21. [An Overview of Global Breast Cancer From SABCS 2019](#)
22. [Essential Presentations at SABCS 2019](#)
23. [Tesetaxel Plus Capecitabine for Patients With Metastatic Breast Cancer](#)
24. [Interferon-Response Gene Signatures and Resistance to CDK4/6 Inhibitors in Breast Cancer](#)
25. [Monitoring Tumor-Specific Mutations in Early-Stage Breast Cancer With ctDNA](#)
26. [Residual Cancer Burden in TNBC Patients Receiving Neoadjuvant Chemotherapy](#)
27. [Neoadjuvant Alpelisib Plus Nab-Paclitaxel for Triple-Negative Breast Cancer](#)
28. [De-Escalating Care in Breast Cancer: A Surgeon’s Perspective](#)
29. [Management of Glioblastoma in the Elderly](#)
30. [Challenges and Strategies for Developing Checkpoint Inhibitors in Glioblastoma](#)
31. [Early-Stage Approaches for Immune-Related and Other Therapies for Glioblastoma](#)
32. [Importance of Extent of Resection in the Management of Gliosarcoma](#)
33. [Adjuvant T-DM1 for Stage I HER2+ Breast Cancer](#)
34. [Patient Perspectives on T-DM1 vs Paclitaxel/Trastuzumab for HER2+ Early Breast Cancer](#)
35. [New Data Comparing Adjuvant T-DM1 vs Trastuzumab for HER2+ Breast Cancer](#)
36. [Ladiratumumab Vedotin Plus Pembrolizumab for Advanced TNBC](#)
37. [Scalp Cooling for Prevention of Chemotherapy-Induced Alopecia](#)
38. [Second Primary Malignancies Among Glioblastoma Survivors](#)

39. [Importance of Tumor-Treating Fields Dosimetry for Patients With Newly Diagnosed Glioblastoma](#)
40. [Chemotherapy in the Management of Central Neurocytoma](#)
41. [Chemotherapy Alone for Oligodendroglioma](#)
42. [Combination of Tumor-Treating Fields and Paclitaxel in Metastatic Non–Small Cell Lung Cancer](#)
43. [Important Updates on Tumor-Treating Fields](#)
44. [Proton Craniospinal Irradiation for Leptomeningeal Disease](#)
45. [Second Interim Analysis From a Phase III Trial on Concurrent and Adjuvant Temozolomide for Anaplastic Glioma Without 1p/19q Codeletion](#)
46. [Toca 511 and Toca FC for Recurrent High-Grade Glioma](#)
47. [Important Presentations From SNO 2019](#)
48. [GammaTile Permanent Implants for Recurrent Brain Tumors](#)
49. [Advance Care Planning and Serious Illness Conversations](#)
50. [Circulating Myeloid-Derived Suppressor Cells as a Predictor for Patients Treated With Nivolumab and Bevacizumab for Recurrent GBM](#)
51. [Update on Immunotherapy and Targeted Therapy for Brain Metastases](#)
52. [Tumor-Treating Fields and Tumor Growth Patterns](#)
53. [Nivolumab Versus Bevacizumab for Recurrent GBM](#)
54. [Phase 0 Immunotherapy Clinical Trials in Neuro-Oncology](#)
55. [Predicting Development of Venous Thromboembolism in Glioblastoma](#)
56. [Anti-IDH 1 Vaccine Among Patients With Low-Grade Glioma](#)
57. [Targeted Therapy for IDH1 Mutant Low-Grade Glioma](#)
58. [VAL-083 for Patients With MGMT-Unmethylated Glioblastoma](#)
59. [Overview of KRAS-Mutant Lung Adenocarcinoma](#)
60. [Circulating Tumor DNA and Tumor Mutational Burden in Non–Small Cell Lung Cancer](#)
61. [Patient-Centered Communication Among Patients With Hematologic Malignancies](#)
62. [Dietary Changes Among Cancer Survivors](#)
63. [Targeting HIF-2a in the Management of vHL-Associated RCC](#)
64. [Monitoring Immunotherapy Outcomes With Circulating Tumor DNA](#)
65. [Sequencing Checkpoint Inhibitors and Stereotactic Radiosurgery for Patients With Brain Metastases](#)
66. [An Overview of Immunotherapy in Bladder Cancer](#)
67. [Checkpoint Inhibitors in the Neoadjuvant Treatment of Triple-Negative Breast Cancer](#)
68. [FGFR Inhibitors in Bladder Cancer](#)
69. [An Overview of Pancreatic Cancer](#)
70. [NEPA for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea/Vomiting](#)
71. [Circulating Tumor DNA in Patients With Brain Tumors](#)
72. [Concurrent HER2-Directed Therapy and Stereotactic Radiosurgery for Breast Cancer Brain Metastases](#)
73. [Harnessing the Immune System in Pancreatic Cancer](#)
74. [Breast Cancer Navigation and Survivorship Care](#)
75. [Role of Checkpoint Inhibition for Localized Bladder Cancer](#)

76. [Use of Colony-Stimulating Factors Among Patients Receiving Intermediate-Risk Chemotherapies](#)
77. [Immunotherapy in the Management of Metastatic Triple Negative Breast Cancer](#)
78. [Immunotherapy Versus Chemotherapy Plus Immunotherapy for Advanced Lung Cancer](#)
79. [Current Challenges in Management of Bladder Cancer](#)
80. [Use of Bone Targeted Agents in the Management of Breast Cancer Related Bone Metastases](#)
81. [Granulocyte Transfusions for Patients With Leukemia and Skin and Soft Tissue Infections](#)
82. [Maintenance Immunotherapy After Chemotherapy for Metastatic Bladder Cancer](#)
83. [Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2+ Breast Cancer](#)
84. [Venous Thromboembolism Among Patients With Chemotherapy-Induced Anemia](#)
85. [Prognostic Model for Patients With Metastatic Urothelial Cancer Receiving Checkpoint Inhibitors](#)
86. [HER2 Heterogeneity and Response to Neoadjuvant T-DM1 Plus Pertuzumab](#)
87. [Atezolizumab Plus Bevacizumab for Non-Clear Cell Renal Cell Carcinoma](#)
88. [Atezolizumab With Adjuvant Chemotherapy for Early-Stage Triple Negative Breast Cancer](#)
89. [Survival With Atezolizumab and Nab-Paclitaxel Versus Nab-Paclitaxel Alone Among Patients With Advanced Triple Negative Breast Cancer](#)
90. [Effects of Exercise on Cancer-Related Fatigue and Strength Among Breast Cancer Patients](#)
91. [Apalutamide vs Placebo Plus ADT Among Patients With Metastatic Castrate-Sensitive Prostate Cancer](#)
92. [Immune-Related Adverse Events and Efficacy of Checkpoint Inhibitors in Gastrointestinal Cancer](#)
93. [Nab-Paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Treatment for Pancreatic Adenocarcinoma](#)
94. [Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Newly Diagnosed Myeloma](#)
95. [Isatuximab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Myeloma](#)
96. [Pyrotinib Plus Capecitabine for HER2+ Metastatic Breast Cancer](#)
97. [Alpelisib in the Management of PIK3CA-Mutated Breast Cancer](#)
98. [Ipilimumab and Nivolumab for Melanoma Brain Metastases](#)
99. [Locally Administered IL4 Guided Toxin for Recurrent Glioblastoma](#)
100. [Marizomib and Temozolomide With Radiotherapy for Patients With Newly Diagnosed GBM](#)
101. [Adjuvant Radiation Therapy Versus Chemotherapy After Surgery for Locally Advanced Bladder Cancer](#)
102. [Trilaciclib Plus Topotecan for Patients With Extensive Stage Small Cell Lung Cancer](#)
103. [Lurbinectedin for Second Line Treatment of Small Cell Lung Cancer](#)
104. [Treatment Sequencing of Checkpoint Inhibitors and Chemotherapy for Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer](#)
105. [Neoadjuvant Chemotherapy Plus Nivolumab and BMS-986205 for Muscle Invasive Bladder Cancer](#)
106. [Erlotinib Plus Ramucirumab for EGFR Mutant Lung Cancer](#)
107. [Larotrectinib for Central Nervous System Cancers With TRK Fusions](#)

108. [Neoadjuvant Atezolizumab for Patients With Non-Small Cell Lung Cancer](#)
109. [Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma](#)
110. [Neoadjuvant Trastuzumab and Pertuzumab Plus Chemotherapy Versus T-DM1 and Pertuzumab in HER2+ Breast Cancer](#)
111. [Human Endogenous Retrovirus and Efficacy of Checkpoint Inhibitors in Renal Cell Carcinoma](#)
112. [Precision Immunotherapy for Urothelial Carcinoma](#)
113. [Biomarkers in Renal Cell Carcinoma](#)
114. [Pazopanib for Patients With VHL Disease](#)
115. [Bone Supportive Therapy and Radium-223 for Metastatic Prostate Cancer](#)
116. [Neoadjuvant Chemotherapy for Invasive Lobular Breast Cancer](#)
117. [EarlyR Prognostic Score for Risk Stratification of HR+ Breast Cancer](#)
118. [Tucatinib With Capecitabine and Trastuzumab in Advanced HER2-Positive Breast Cancer](#)
119. [Filgrastim vs Filgrastim Biosimilars for Prevention of Febrile Neutropenia](#)
120. [Circulating Tumor DNA in Metastatic Prostate Cancer](#)
121. [Breast Cancer in Young Adults](#)
122. [Risk Stratification for Metastatic RCC](#)
123. [Real-World Efficacy of Palonosetron Three-Drug Regimen for Highly Emetogenic Chemotherapy](#)
124. [Chemotherapy for Oligometastatic Prostate Cancer](#)
125. [Tivozanib for Refractory Advanced RCC](#)
126. [Zuclomiphene for Hot Flashes Following Androgen Deprivation Therapy](#)
127. [Talazoparib With Enzalutamide for Castration-Resistant Prostate Cancer](#)
128. [Rucaparib for Advanced Urothelial Carcinoma](#)
129. [Pembrolizumab for Patients With High-Risk, Non-Muscle Invasive Bladder Cancer](#)
130. [Androgen Deprivation Therapy Plus Enzalutamide for Hormone-Sensitive Prostate Cancer](#)
131. [Pembrolizumab for Non-Clear Cell RCC](#)
132. [A Novel Tubulin Inhibitor, VERU-111, for mCRPC](#)
133. [PT2977 for VHL-Associated RCC](#)
134. [Implementation of a Community-Based Breast Cancer Management Program in Peru](#)
135. [Ipilimumab Plus Nivolumab for mCRPC](#)
136. [Key Data From ASCO GU 2019 on mRCC](#)
137. [Key Data From ASCO GU 2019 on mRCC: Pembrolizumab and Axitinib as First-Line Therapy](#)
138. [Tucatinib With T-DM1 for HER2-Positive Metastatic Breast Cancer](#)
139. [Metastatic Breast Cancer With Bone-Only Metastases](#)
140. [Panitumumab Plus Chemotherapy for Patients With Inflammatory Breast Cancer](#)
141. [Alpelisib and T-DM1 for HER2-Positive Metastatic Breast Cancer](#)
142. [HIV-Related Malignancies](#)
143. [Atezolizumab, Cobimetinib, and Eribulin in Patients With Metastatic Inflammatory Breast Cancer](#)

144. [Antiemetics for CINV](#)
145. [Race, Ethnicity, and Clinical Outcomes From the TAILORx Trial](#)
146. [Neoadjuvant Talazoparib for BRCA 1/2 Mutated Triple Negative Breast Cancer](#)
147. [Baseline Circulating ESR1 Mutation Analysis From the EFACT Study](#)
148. [Subgroup Analysis of Combination Immunotherapy for Triple Negative Breast Cancer](#)
149. [Expression Score \(Escore\) for Predicting Recurrence of DCIS](#)
150. [Lasofoxifene vs Fulvestrant for HR-Positive Breast Cancer](#)
151. [T-DM1 vs Trastuzumab as Adjuvant Therapy for HER2-Positive Breast Cancer](#)
152. [Adjuvant T-DM1 for HER 2+ Breast Cancer: Critical Data From The KATHERINE Study](#)
153. [New Data and Implications of HER2 Amplification by ctDNA](#)
154. [Eflapegrastim for Reducing Severe Neutropenia](#)
155. [Regional Analysis of Talazoparib for Treatment of Advanced Breast Cancer With Germline BRCA 1/2 Mutation](#)
156. [TAK-228 Plus Hormonal Therapy for Metastatic, ER-Positive/HER2-Negative Breast Cancer](#)
157. [Global Challenges in Lung Cancer](#)
158. [Molecular Profiling](#)
159. [Prognostic Variables in Stage III Melanoma](#)
160. [Cancer-Related Anemia](#)
161. [Combination Immunotherapy in the First Line Treatment of NSCLC](#)
162. [Cost Efficiency and Checkpoint Inhibitors for Urothelial Carcinoma](#)
163. [Growth Factors and Febrile Neutropenia](#)
164. [Heroin/Opioid Addiction Among Cancer Patients—Recommendations for Patients](#)
165. [TKIs and Tolerability in the Treatment of Metastatic RCC](#)
166. [Heroin/Opioid Addiction Among Cancer Patients—Role of Advanced Practice Nurse](#)
167. [VHL and Neuroendocrine Tumors](#)
168. [Heroin/Opioid Addiction Among Cancer Patients—Non-Opioid Pain Management](#)
169. [Updates on Lung Cancer With a Driver Mutation](#)
170. [Health Disparities and Breast Cancer](#)
171. [Bortezomib-based Chemotherapy and Light Chain Amyloidosis](#)
172. [Updates on CDK 4/6 Inhibitors in Metastatic Breast Cancer](#)
173. [Heroin/Opioid Addiction Among Cancer Patients—Signs of Abuse](#)
174. [Global Health in Breast Cancer](#)
175. [Chemotherapy for Elderly Patients With Bladder Cancer](#)
176. [A New Standard of Care in Lung Cancer?](#)
177. [R-ISS for Transplant-eligible Multiple Myeloma Patients](#)
178. [Top Advance in Breast Cancer From ASCO 2018](#)
179. [CXCR4 Antagonists and Breast Cancer](#)
180. [EGFR Inhibitors for CNS Metastases From NSCLC](#)
181. [TTFIELDS for Non-GBM Indications](#)
182. [Adjuvant Therapy for Resected Stage III Melanoma](#)
183. [PARP Inhibitors in Breast Cancer](#)
184. [Non-Clear-Cell Renal Cell Carcinomas](#)

185. [Comparative Effectiveness of Checkpoint Inhibitors in Lung Cancer](#)
186. [Immunotherapy and Urothelial Cancer](#)
187. [TFields for Management of GBM](#)
188. [ASCO 2018: Antibody-Drug Conjugate Shows Promise in Glioblastoma](#)
189. [Lung Cancer Studies at ASCO 2018](#)
190. [ASCO 2018: Critical Practice Impacting Trials in GU Oncology](#)
191. [ASCO 2018: The Implications of Race in Prostate Cancer](#)
192. [Melanoma Trials at ASCO 2018](#)
193. [Bladder Cancer at ASCO 2018](#)
194. [Biomarkers in GU Cancers](#)
195. [ASCO 2018: PD-1 and CTLA-4 Blockade Following Progression on a PD-1 Inhibitor in Advanced Melanoma](#)
196. [ASCO 2018: Current Concepts in the Management of Uveal Melanoma](#)
197. [ASCO 2018: Novel Ways to Improve Lung Cancer Screening](#)
198. [Practice Impacting Data on Metastatic Breast Cancer From ASCO 2018](#)
199. [ASCO 2018: An Overview of Clinical Trials in Urothelial Carcinoma](#)
200. [ASCO 2018: Advances and Future Directions for Vaccines for Glioblastoma](#)
201. [Contemporary Adjuvant and Neoadjuvant Therapy for Breast Cancer: The Surgeon's Perspective](#)
202. [Proteasome Inhibitors in GBM](#)
203. [Novel Approaches for HER2-Negative Metastatic Breast Cancer](#)
204. [ASCO 2018: A Review of Current and Upcoming Data on Neoadjuvant Immunotherapy for Melanoma](#)
205. [ASCO 2018: New Genomic Insights in Urothelial Carcinoma](#)
206. [Multiple Myeloma at ASCO 2018](#)
207. [Applying Clinical Trial Findings in Patients With Multiple Myeloma](#)
208. [ASCO 2018: Implications for the Clinician of the New AJCC Staging System for Melanoma](#)
209. [ASCO 2018: Predicting Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PDL-1 Inhibitors](#)
210. [ASCO 2018: New Phase 3 Data on PD-L1 vs Chemotherapy for First-Line NSCLC](#)
211. [ASCO 2018: New Data on Appropriate Selection of Non-Clear Cell mRCC Patients for Immunotherapy](#)
212. [ASCO 2018: Practice Implications of Real World Data on First-Line Pazopanib in mRCC](#)
213. [The 3 Top Advances in Radiation Oncology From ASCO 2018](#)
214. [Genitourinary Cancer at ASCO 2018](#)
215. [ASCO 2018: New Evidence and Implications for Integrating NEPA for CINV](#)
216. [ASCO 2018: Potential Role for PARP Inhibitor and PD-L1 Inhibitor Combination in Metastatic Triple Negative Breast Cancer](#)
217. [An Overview of Rarer Subtypes of Kidney Cancer](#)
218. [Genomic Profiling of Bladder Cancer](#)
219. [Contemporary Neoadjuvant Management of Bladder Cancer](#)

220. [Implications on PSMA Targeted Therapy](#)
221. [Practical Implications of Emerging Data on Radiation Therapy for CNS Tumors](#)
222. [Current Concepts in Therapeutic Selection for Brain Metastases](#)
223. [Consequences of VHL Loss](#)
224. [Current Evidence on Frontline Therapy for mRCC](#)
225. [Evidence-Based Chemotherapy for Oligometastatic Prostate Cancer](#)
226. [Current Concepts in the Treatment of Non-Clear Cell Kidney Cancer](#)
227. [Critical Updates on Response Assessment for CNS Tumors](#)
228. [New Concepts in Tumor-Related Epilepsy](#)
229. [Current Concepts in the Management of VHL](#)
230. [Managing Immunotherapy Toxicity in the Community Setting](#)
231. [Data Updates and Current Concepts in Proton Therapy](#)
232. [Contemporary Management of Penile Cancer](#)
233. [Future Directions for GBM: A Multidisciplinary Review](#)
234. [New Insights Into Squamous Cell Carcinoma of the Bladder](#)
235. [Genomic Profiling in Kidney Cancer](#)
236. [How I Use PD-1 Inhibitors in RCC](#)
237. [Bevacizumab in Glioblastoma: A Review of Recent Data](#)
238. [Updates on Papillary Renal Cell Carcinoma From ASCO GU 2018](#)
239. [Evidence-Based Use of Immunotherapy in GBM: An Expert Review](#)
240. [A Review of Histologic Prognostic Variables in Breast Cancer](#)
241. [ASCO GU 2018: A New Prognostic Model for Urothelial Carcinoma](#)
242. [An Overview of Urothelial Cancer Treatment From ASCO GU 2018](#)
243. [A Review of Urothelial Cancer Trials From ASCO GU 2018](#)
244. [Combination Therapies in mRCC: Updates From ASCO GU 2018](#)
245. [Updates on the Role of IMDC Risk Groups in Kidney Cancer From ASCO GU 2018](#)
246. [Key Features of Micropapillary Urothelial Carcinoma and Their Clinical Implications: ASCO GU 2018](#)
247. [Potential Role for High Dose IL-2 in mRCC: New Data From ASCO GU 2018](#)
248. [New Insights on Immune-Related Adverse Events in GU Cancers From ASCO GU 2018](#)
249. [Perspectives on Atezolizumab in Urothelial Cancer From ASCO GU 2018](#)
250. [ASCO GU 2018: Enzalutamide vs Bicalutamide for Metastatic Hormone Sensitive Prostate Cancer](#)
251. [Comparative Data on First Line mCRPC From ASCO GU 2018](#)
252. [Implications of Real World Data on Nivolumab in mRCC From ASCO GU 2018](#)
253. [Contextualizing PROSPER Data: Recommendations From ASCO GU 2018](#)
254. [Radium-223 in mCRPC: Updates From ASCO GU 2018](#)
255. [ASCO GU 2018: New Genomic Data on the Management of VHL-Mutated Clear Cell RCC](#)
256. [Adjuvant Sunitinib in Renal Cell Carcinoma: An Update From ASCO GU 2018](#)
257. [Practical Aspects of Adjuvant Renal Cell Carcinoma Therapy: Insights From ASCO GU 2018](#)
258. [Utilizing ctDNA in Urothelial Cancer: Insights From ASCO GU 2018](#)

259. [First Line Checkpoint Inhibitors for mRCC: Updates From ASCO GU 2018](#)
260. [Genomic Profiling for Breast Cancer Patients Undergoing Immunotherapy](#)
261. [New Developments in the Management of Brain Metastases](#)
262. [Future Directions for Liquid Biopsies in Breast Cancer](#)
263. [Integrating New Diagnostic Technologies in the Management of GBM](#)
264. [Global Challenges and Successes in Cancer Care](#)
265. [Current Concepts in Genomic Profiling for Breast Cancer](#)
266. [Sequencing Endocrine Therapies for ER+ Breast Cancer](#)
267. [Recommendations on Radiation Therapy for Meningiomas](#)
268. [Perspectives on Radiation Therapy in Combination With Immunotherapy and TT Fields](#)
269. [Key NCCN Guideline Updates for CNS Tumors](#)
270. [Z-Endoxifen for Endocrine Refractory Breast Cancer: An Update](#)
271. [Personal and Professional Rehabilitation for Breast Cancer Patients](#)
272. [Novel Directions for HER2+ Breast Cancer](#)
273. [Perspectives on Combination Radiotherapy for Brain Cancer](#)
274. [Using Biomarkers to Plan Adjuvant Therapy in Breast Cancer](#)
275. [Tumor Treating Fields: Practical and Clinical Insights](#)
276. [Updates on Contemporary Management of ER+ Metastatic Breast Cancer](#)
277. [An Overview of Clinically Significant Mutations in Glioma](#)
278. [Elsevier's Journal of Bone Oncology: A Review With E-I-C Prof. Robert Coleman](#)
279. [Supportive Care and Quality of Life in Patients With Brain Tumors](#)
280. [Practical Considerations in Managing Neutropenia in Breast Cancer](#)
281. [Practical Considerations in Managing Early HER2+ Breast Cancer](#)
282. [Considerations and Recommendations for Sequencing Therapy for HER2+ Advanced Breast Cancer](#)
283. [Identifying Patients for Cytoreductive Nephrectomy in RCC](#)
284. [Preservation of Function in Breast Cancer Patients: New Insights From SABCS 2017](#)
285. [SABCS 2017: Subgroup Analyses and Patient Selection for CDK4/6 Inhibitor Therapy](#)
286. [Key Trials in Metastatic Breast Cancer From SABCS 2017](#)
287. [Practice Changers From SABCS 2017](#)
288. [Disparities in the Incidence and Mortality of Breast Cancer Based on Patient Subtypes: SABCS 2017](#)
289. [Selection of CDK 4/6 Inhibitor Based on New Data From SABCS 2017](#)
290. [Estimating Outcomes in Triple Negative Breast Cancer From SABCS 2017](#)
291. [Updates on CDK4/6 Inhibitor Therapy From SABCS 2017](#)
292. [Clinical Updates on Advanced Triple Negative Breast Cancer From SABCS 2017](#)
293. [New Data and a Review of Bisphosphonate Use in Breast Cancer From SABCS 2017](#)
294. [SABCS 2017: An Update on Hepatic Pseudocirrhosis in Breast Cancer](#)
295. [SABCS 2017: Key Takeaways From Dr. Jame Abraham](#)
296. [New Data on the Second Line Treatment of HER2+ Breast Cancer From SABCS 2017](#)
297. [Selected Novel Agents and Targets in Breast Cancer From SABCS 2017](#)
298. [New Data on Measures of Breast Cancer Aggressiveness From SABCS 2017](#)
299. [Radiation and Immunotherapy: Novel Concepts From SABCS 2017](#)

300. [Contextualized Updates in HER2+ Breast Cancer From SABCS 2017](#)
301. [Tumor Treating Fields—The Radiation Oncology Perspective](#)
302. [New Modalities for Genomic Profiling of HER2+ Breast Cancer From SABCS 2017](#)
303. [New Data on Androgen Receptor Blockade in Breast Cancer: A Review From SABCS 2017](#)
304. [Clinical Utility of Circulating Tumor Cells and Cell-Free Tumor DNA in Breast Cancer](#)
305. [Systemic Therapy for Local Recurrence of Breast Cancer: An Overview From SABCS 2017](#)
306. [Glioblastoma Therapeutic Review From SNO 2017](#)
307. [Hypermutator Phenotypes and Genomic Analyses of Gliomas: Updates From SNO 2017](#)
308. [New Data on the Management of Recurrent GBM From SNO 2017: Practical Implications](#)
309. [Re-irradiation for CNS Tumors: New Data and a Critical Review From SNO 2017](#)
310. [Treatment Strategies for Systemic Sclerosis](#)
311. [New Data and Current Concepts in High Risk Meningioma From SNO 2017](#)
312. [Gene Therapy for GBM: New Data and Perspectives From SNO 2017](#)
313. [Contemporary Utilization of Imaging in Planning and Assessing GBM Treatment](#)
314. [New Developments in Radiation Therapy for Gliomas and Glioblastomas From SNO 2017](#)
315. [Key Trials on Glioblastomas at SNO 2017](#)
316. [Key Trials on Gliomas at SNO 2017](#)
317. [Risk Factors for Systemic Lupus Erythematosus](#)
318. [Novel Agents for GBM: A Review of Trials at SNO 2017](#)
319. [Novel Agents for GBM and Glioma From SNO 2017](#)
320. [A Review of Major Trials From SNO 2017: The Medical Oncology Perspective](#)
321. [A Review of Major Trials From SNO 2017: The Radiation Oncology Perspective](#)
322. [New Data on the Management of Recurrent Glioblastoma and High Grade Glioma](#)
323. [New Data on Immune Checkpoint Inhibitors in Glioblastoma From SNO 2017](#)
324. [Managing Risk Factors for RA](#)
325. [Basket Trials and Liquid Biopsies: New Frontiers in Cancer Research](#)
326. [Combining Rheumatology and Infectious Disease: A Practical Guide](#)
327. [Musculoskeletal Ultrasound in Rheumatology Practice](#)
328. [Withdrawal of DMARDs in RA Patients in Remission: New Data](#)
329. [Regaining Remission in Rheumatoid Arthritis Flares](#)
330. [Key Trials in RA From ACR/ARHP 2017](#)
331. [Smoking and the Risk of RA](#)
332. [Key TakeAways From ACR/ARHP 2017](#)
333. [Structured Patient Involvement in Rheumatoid Arthritis Care](#)
334. [Intra-Articular Steroids for Knee Osteoarthritis: Patient Selection and Recommendations](#)
335. [RA Patients With Early and Advanced Disease](#)
336. [Measuring RA Treatment Effect With Ultrasound: Clinical Recommendations](#)
337. [Cardiovascular Risk in Seniors With Newly Diagnosed RA](#)

338. [Depression as a Risk Factor for RA](#)
339. [Immunotherapy-Induced Diseases: A New Paradigm for Rheumatologists](#)
340. [Fish Consumption as an Adjunctive Treatment for RA](#)
341. [Maintaining Bone Health in Cancer Patients: An Overview](#)
342. [Managing Cancer Related Anemia: A Practical Guide](#)
343. [Promising New Therapies for Myeloma](#)
344. [Extent of Lymph Node Dissection for Bladder Cancer](#)
345. [Practical Updates in Melanoma](#)
346. [Should Colon Cancer Treatment Depend on Tumor Location?](#)
347. [Pembrolizumab and IDO Inhibitors in Bladder Cancer](#)
348. [Skin Cancer Updates: Select Trials Reviewed](#)
349. [Integrating Genetic Testing for Prostate Cancer in Clinical Practice](#)
350. [My Approach to Utilizing Molecular Markers in Prostate Cancer](#)
351. [New Data on Bone Supportive Health in Prostate Cancer](#)
352. [Practice Changes in Advanced Prostate Cancer](#)
353. [An Overview of Genomics in GU Oncology](#)
354. [Current Status of Immunotherapy for Glioblastoma](#)
355. [Current Thinking on the Role of Steroids in Neuro-Oncology](#)
356. [Key Strategies for Treating Elderly Patients With Glioblastoma](#)
357. [Biomarkers and Targeted Therapies for Glioblastoma](#)
358. [The Role of Nephrectomy in the Context of Targeted Therapy for RCC](#)
359. [Practical Aspects of Nutrition Counseling in Breast Cancer](#)
360. [Mitigating Long-Term Neurotoxicity From Radiation in Neuro-Oncology](#)
361. [Maximizing Patient Compliance With Tumor Treating Fields](#)
362. [Patient-Related Factors and Issues in Using TTFs for Glioblastoma](#)
363. [New Data on Immunotherapy for Bladder Cancer: Part 1](#)
364. [Predictive Factors for Immunotherapy in Bladder Cancer: Part 2](#)
365. [Mechanism of Action of Tumor Treating Fields: Clinical Implications](#)
366. [Patrick Wen on Advances in Glioma Treatment](#)
367. [Novel Therapies and Future Directions in Anaplastic Thyroid Carcinoma](#)
368. [RCC Updates: Adjuvant Therapy and Non-Clear Cell Cancers](#)
369. [Current Concepts in Stem Cell Transplantation for Multiple Myeloma](#)
370. [Practical Recommendations for Circulating Tumor Cells in Prostate Cancer](#)
371. [Translational Medicine in NeuroOncology: Progress in Meeting Unmet Needs](#)
372. [Recommendations for Sequencing Glioblastoma Treatments](#)
373. [Updated Recommendations for Primary CNS Lymphoma](#)
374. [Tumor Biology and Sidedness in Colon Cancer: New Insights From ASCO 2017](#)
375. [Sequencing Therapy for Metastatic RCC: An Evidence-Based Analysis](#)
376. [Current Concepts in the Treatment of Brain Metastases from Breast Cancer](#)
377. [Updates in the Treatment of Brain Metastases](#)
378. [A Multidisciplinary Approach High Grade and Low Grade Gliomas: The Penn Experience](#)
379. [Addressing Prognosis, QoL, Adverse Events and Goals of Care in Neuro-Oncology](#)
380. [Looking Beyond R-CHOP in Diffuse B-Cell Lymphoma](#)

381. [Key Issues Impacting RCC and Urothelial Cancer: A Review of Recent Trials](#)
382. [Novel Combinations for Relapsed/Refractory Multiple Myeloma From ASCO 2017](#)
383. [ASCO 2017: Practice Impact of New Data and Recommendations for Multiple Myeloma](#)
384. [A Review of Trials on HER2+ Breast Cancer From ASCO 2017](#)
385. [Updates on Von Hippel Lindau Disease From ASCO 2017](#)
386. [Second Line Pembrolizumab vs Chemotherapy in Bladder Cancer: Insights From ASCO 2017](#)
387. [Molecular Analysis of Bladder Cancer From ASCO 2017: Clinical Implications](#)
388. [Practice Changers in Myeloma From ASCO 2017](#)
389. [Key Practice Changers in GU Oncology From ASCO 2017](#)
390. [Updates on Checkpoint Inhibitors and TTFIELDS in CNS Oncology From ASCO 2017](#)
391. [New Data on Liquid Biopsies in Breast Cancer](#)
392. [Evidence-Based Approaches in Early Breast Cancer From ASCO 2017](#)
393. [Practice Updates in Anaplastic Thyroid Carcinoma From ASCO 2017](#)
394. [Clinically Relevant Data on Soft Tissue Sarcoma From ASCO 2017](#)
395. [Clinical Updates on the Management of Febrile Neutropenia From ASCO 2017](#)
396. [CINV Updates and Comparative Trials at ASCO 2017](#)
397. [Critical Trial Review in GU Oncology From ASCO 2017](#)
398. [ASCO 2017 Updates on Managing Brain Metastases From Cancer: A Focus on Breast Cancer](#)
399. [Implications of New Data in Colon Cancer From ASCO 2017](#)
400. [A Contextual Review of New Data in Lymphoma Treatment](#)
401. [BRCA Mutations in Breast Cancer: Clinically Relevant New Data](#)
402. [The Role of Immune Therapy in Glioblastoma: Implications of New Data](#)
403. [New Concepts in the Management of HER2+ Breast Cancer](#)
404. [A Recap of Key New Data in Breast Cancer](#)
405. [Updates in Bladder Cancer: New Treatments and Better Genomic Analyses](#)
406. [New Data on Brain Metastases: The Role of Immune Therapy](#)
407. [Alternative Scheduling of Sunitinib and Newer Therapies for RCC: An Update From ASCO 2017](#)
408. [Practice Changers in Breast Cancer From ASCO 2017](#)
409. [Mechanisms of Resistance and Personalized Medicine in Breast Cancer](#)
410. [Practice Implications of BRCA Mutations From ASCO 2017](#)
411. [Key Trials on Brain Metastases From ASCO 2017](#)
412. [Key Trials in CNS Oncology From ASCO 2017](#)
413. [Key Trial Data on Lymphoma From ASCO 2017: Implications for Clinical Practice](#)
414. [Key Practice Changers From ASCO 2017](#)
415. [Extent of Lymph Node Dissection in Prostatectomy: An Update From ASCO 2017](#)
416. [An Update on Meningioma Treatments: Current Options and New Research](#)
417. [Addressing BRAF Mutations in Colon Cancer: New Data From ASCO 2017](#)
418. [Mitoxantrone and Veliparib in Prostate Cancer: Updates From ASCO 2017](#)
419. [ASCO 2017: Dr. David Henry on Preventing Febrile Neutropenia](#)
420. [Dr. David Henry Contextualizes CINV Data From ASCO 2017](#)

421. [The New Standard of Care? Abiraterone in Metastatic Prostate Cancer](#)
422. [ASCO 2017: Clinically Relevant Genomic Insights for Breast Cancer Management](#)
423. [Practice Changers in Advanced Prostate Cancer From ASCO 2017: STAMPEDE, LATITUDE vis-à-vis CHAARTED](#)
424. [A New Standard of Care for Low Risk Stage III Colorectal Cancer?: ASCO 2017 Update](#)
425. [Key Updates from the CNS Panel in the 2016 NCCN Guidelines](#)
426. [Promising Investigational Treatment for Bladder Cancer](#)
427. [MY APPROACH to Dosing Schedules for Sunitinib](#)
428. [An Overview of PD-1 Inhibitors in Bladder Cancer](#)
429. [Management of Renal Medullary Cancer: A Multidisciplinary Review](#)
430. [MY APPROACH to the Surgical Management of Low Grade Gliomas](#)
431. [Updates on the Neoadjuvant Treatment of Breast Cancer](#)
432. [Management of Medical Emergencies in Brain Tumor Patients](#)
433. [Managing Mineralocorticoid Excess in mCRPC: Data Review and Clinical Recommendations](#)
434. [New Options for Papillary RCC](#)
435. [Evidence-Based Recommendations for Second-Line RCC Treatment](#)
436. [New Data on Patient-related Factors and Compliance With Tumor Treating Fields](#)
437. [IDH Inhibitors in IDH-Mutant Low-Grade and High-Grade Gliomas: A Review of Current Data](#)
438. [Updates on Molecular Profiling for Breast Cancer: Part 2](#)
439. [Sunitinib or PD-1 as Frontline RCC Therapy: A Conceptual Review](#)
440. [Management of Aggressive Prostate Cancer Variants](#)
441. [Neurological Complications From Cancer](#)
442. [Implications of Nephrectomy Technique for RCC Outcomes](#)
443. [Updates on Molecular Profiling for Breast Cancer: Part 1](#)
444. [Integrating CDK 4/6 Inhibitors Into the Care of Premenopausal Women With Breast Cancer](#)
445. [Management of Papillary and Collecting Duct Kidney Cancer](#)
446. [Gene Profiling and Role of Radiation in GU Cancers](#)
447. [Current Concepts in the Treatment of Bladder Cancer and Germ Cell Tumors](#)
448. [Current Data on RCC Therapy: Sunitinib Dosing, Combination Therapy, and More](#)
449. [Triple Negative Breast Cancer Treatment Update: Capecitabine, Immunotherapy and Platinum Salts](#)
450. [A Comparison of PCV and Temozolomide: Clinical Perspectives and a Review of Data](#)
451. [MY APPROACH to Systemic Therapy vs Re-Irradiation vs TTFIELDS in Recurrent Glioblastoma](#)
452. [Practical Considerations in Integrating HER2 Biosimilars in Clinical Practice](#)
453. [Growth Factors in Managing Infection-Related Outcomes in mCRPC](#)
454. [The Role of High-Dose Interleukin in RCC](#)
455. [Dosing and Combinations of Sunitinib Vis-à-Vis Alternative Therapies for RCC](#)
456. [Integrating Molecular Genetics Into Breast Cancer Patient Care](#)
457. [Incorporating TTFIELDS in Glioblastoma Treatment: Practical Implications](#)

458. [Determining Endocrine Therapy for Premenopausal Breast Cancer Patients: Practical Considerations](#)
459. [Immune Checkpoint Inhibitors, Androgen Receptors, Targeted Agents and Personalized Medicine: New Directions in Breast Cancer](#)
460. [An Overview of Radium Therapy and PD-1 Agents for Prostate Cancer](#)
461. [MY APPROACH to Platinum-Ineligible Bladder Cancer Patients](#)
462. [Current Concepts in Initial and Adjuvant RCC Treatment](#)
463. [Bladder Cancer Highlights From ASCO GU 2017: Clinical Implications](#)
464. [Adding Anthracyclines for HER2+ Disease](#)
465. [Combination Treatment of HER2+ Metastatic Breast Cancer: Second-Line Therapy](#)
466. [Combination Treatment of HER2+ Metastatic Breast Cancer: First-Line Therapy](#)
467. [Current Status of Immune Checkpoint Inhibitors for Breast Cancer](#)
468. [Acupuncture in Breast Cancer Care: Practical Issues and Data Review](#)
469. [Highlights of SNO 2016: TTFIELDS, Immunotherapy, New WHO Classification and More](#)
470. [Clinical Implications of Molecular Subtypes in Bladder Cancer and Updates on Germ Cell Tumor Therapy From ASCO GU 2017](#)
471. [Micro RNA and Luminal vs Basal Subtypes in Advanced Prostate Cancer: Clinical Implications From ASCO GU 2017](#)
472. [Major Trial Data From ASCO GU 2017: An Overview](#)
473. [The Role of Cytoreductive Nephrectomy in RCC: Current Insights From ASCO GU 2017](#)
474. [Chemoradiotherapy for Bladder Cancer: Clinical Relevance of Data From ASCO GU 2017](#)
475. [Genomic Testing and Subtyping in Prostate Cancer: The Urology Perspective From ASCO GU 2017](#)
476. [Key Trials on Advanced Prostate Cancer From ASCO GU 2017](#)
477. [Management of Rare Kidney Cancers: Recommendations From ASCO GU 2017](#)
478. [Current Concepts in Adjuvant Therapy for RCC From ASCO GU 2017](#)
479. [Exercise for Advanced Prostate Cancer and Updates on Urethral Cancer and Penile Cancer From ASCO GU 2017](#)
480. [Circulating DNA vs Conventional Biopsy for GU Cancers: A Review From ASCO GU 2017](#)
481. [Frontline Systemic Therapy for RCC: An Overview From ASCO GU 2017](#)
482. [Practical Implications of ctDNA in RCC: New Data From ASCO GU 2017](#)
483. [An Overview of ctDNA in GU Cancers and Other Highlights From ASCO GU 2017](#)
484. [Neoadjuvant Therapy for RCC From ASCO GU 2017: A Review](#)
485. [Key Data on mCRPC From ASCO GU 2017: Chemotherapy for Newly Diagnosed Patients and Molecular Profiling](#)
486. [Emerging Data on Vaccines and Circulating DNA in RCC From ASCO GU 2017](#)
487. [Key RCC Data From ASCO GU 2017: TKIs, Immunotherapy, Alternative Scheduling, and QoL](#)
488. [PD-1 Combination Therapy for RCC: An Update From ASCO GU 2017](#)
489. [RCC Highlights From ASCO GU 2017](#)
490. [Key Data on Bladder Cancer From ASCO GU 2017](#)
491. [Chemoradiation in Bladder Cancer: A Review From ASCO GU 2017](#)

492. [The Role of Molecular Markers in Bladder Cancer From ASCO GU 2017](#)
493. [Non–Muscle Invasive and Muscle-Invasive Bladder Cancer Data From ASCO GU 2017](#)
494. [Clinical Considerations When Integrating CDK4/6 inhibitors](#)
495. [New Combination Options for HR+ Patients: An Update from SABCS 2016](#)
496. [Predictive Markers for Breast Cancer: An Overview From SABCS 2016](#)
497. [New Data on CDK 4/6 Inhibitors: An Update From SABCS 2016](#)
498. [PI3K Inhibitors Data Review: How Do They Compare With CDK4/6 inhibitors, mTOR inhibitors, AIs and Other Classes for HR+ Breast Cancer](#)
499. [Bone Health and Bisphosphonates in Breast Cancer: An Overview](#)
500. [Liquid Biopsies' and Endocrine Therapy: An Update From SABCS 2016](#)

501. [Current Concepts in Managing Brain Metastases in Patients With Breast Cancer](#)
502. [Axillary Nodes After Neoadjuvant Treatment: An Update From SABCS 2016](#)
503. [New Options for HR+ Breast Cancer: An Update From SABCS 2016](#)
504. [New Data on Managing HER2+ Disease From SABCS 2016](#)
505. [Circulating DNA Markers for Breast Cancer: A Review of New Data From SABCS 2016](#)
506. [New Insights From SABCS 2016 on Adjuvant Therapy for HR+ Breast Cancer](#)
507. [Precision Medicine in Breast Cancer: Two New Options From SABCS 2016](#)
508. [Management of HER2+ Cancers: Integrating New Data Into Clinical Practice](#)
509. [Current Advances and Research in Breast Cancer: An Overview](#)
510. [An Overview of Immunotherapy in Thoracic Cancer by Roy Herbst](#)
511. [Developing a Multidisciplinary Team for Breast Cancer Care](#)
512. [Current Concepts in the Management of Brain Metastases: An Update from SNO 2016](#)
513. [Improved Survival with TTFIELDS and Temozolomide in Newly Diagnosed Glioblastoma: A Conversation With Roger Stupp at SNO 2016](#)
514. [Checkpoint Inhibitors, Viral Therapies and Other Novel Options for Glioblastoma: An Update from SNO 2016](#)
515. [New Options for Leptomeningeal Metastases: A Review from SNO 2016](#)
516. [Clinical Implications of New Data from SNO 2016 on the Treatment of Low Grade Gliomas](#)
517. [Emerging Compounds and Strategies for RCC Treatment](#)
518. [Practice Changers from SNO 2016: A Discussion with Santosh Kesari](#)
519. [Current Recommendations for the Multidisciplinary Management of Glioblastoma from SNO 2016](#)
520. [Current Status of Vaccines and Immunotherapy in High Grade Gliomas: An Update from SNO 2016](#)
521. [ACT IV Study Failure: Implications for Vaccine Therapy in High Grade Glioma From SNO 2016](#)
522. [A Review of Precision Medicine in NeuroOncology From SNO 2016](#)
523. [Predictors of Immunotherapy Response in Lung Cancer: Biomarkers, Mutational Load and Tumor Biology](#)
524. [Critical Management Scenarios: Large Cell Lymphoma Beyond R-CHOP and High Risk Follicular Lymphoma Patients](#)

525. [Determining the Duration of Aromatase Inhibitor Therapy: An Interview With Reshma Mahtani](#)
526. [Mechanisms and Implications of HER2 Resistance: An Interview With Dr. William Gradishar](#)
527. [An Overview of Immunotherapy in Breast Cancer](#)
528. [Current Research on Immunotherapy in Bladder Cancer](#)
529. [Roy Herbst on Proton Therapy vs Conventional Radiation Therapy in the Treatment of Early NSCLC](#)
530. [An Overview of Immunotherapy in Breast Cancer: An Interview With Adam Brufsky](#)
531. [The Evolving Role of the Advanced Practice Nurse in Oncology: A Conversation With Lillie Shockney](#)
532. [Kimberly Blackwell on Advances in the Management of HER2+ Patients](#)
533. [The Role of Gene Expression Profiles in Determining Early Therapy in Breast Cancer](#)
534. [New Paradigms in the Treatment of Mesothelioma and NSCLC: An Overview by Fred Hirsch](#)
535. [Sumanta Pal on the Molecular Signatures of Risk and Response in RCC](#)
536. [Patient Empowerment and End-of-Life Planning: The Role of the Nurse Navigator](#)
537. [Advances in Immunotherapy for Small Cell Lung Cancer](#)
538. [Perspectives on Therapeutic Toxicity in RCC](#)
539. [Precision Medicine: Current Status and Near-Term Implications \(Part 2\)](#)
540. [Precision Medicine: Current Status and Near-Term Implications \(Part 1\)](#)
541. [Dr. Patrick Wen on Advances in Glioblastoma Treatment](#)
542. [Advances in Genomic Testing and Computational Biology for Breast Cancer](#)
543. [Future Directions in Breast Cancer: A Conversation With Dr. Lee Schwartzberg](#)
544. [HER2 Biosimilars in Clinical Practice: An Interview With Dr. William Gradishar](#)
545. [Hematology Practice Implications: New Hodgkin's Lymphoma Research](#)
546. [Future of Immunotherapy and Biomarkers in Prostate Cancer](#)
547. [Tissue Biopsy, Biomarkers and Precision Medicine in Prostate Cancer](#)
548. [Hematology Practice Implications: New Large Cell Lymphoma Research](#)
549. [Micro RNAs in Brain Cancer Treatment](#)
550. [Preventing Castrate-Resistant Disease: Future Directions](#)
551. [Proteasome Inhibitors in Advanced Castrate-Resistant Prostate Cancer](#)
552. [Perspectives on First-Line RCC Treatment Following the CheckMate Trial](#)
553. [Genetic Testing in Patients With Relevant Family History in Prostate Cancer](#)
554. [Hematology Practice Implications: New Adult T-Cell Lymphoma Research](#)
555. [New Clinical Trials in RCC: VEGF Therapy Pairings](#)
556. [Advances in Biomarkers for Brain Cancer Precision Medicine](#)
557. [Gene Therapy Advances in Glioblastoma](#)
558. [Role of Biomarkers in Therapy Selection for Upfront Hormone-Sensitive Prostate Cancer](#)
559. [Review of Clinically Relevant New Research in Prostate Cancer](#)
560. [Role of VEGF/TKIs in Priming Tumors for Checkpoint Inhibitors in RCC: Sequencing Implications](#)

561. [Combination Therapy Data in RCC From ASCO](#)
562. [Surgical vs Intermittent Castration for Prostate Cancer](#)
563. [RCC Therapeutic Challenges: Checkpoint Inhibitors IL-2 and Sequencing VEGF Inhibitors](#)
564. [Immunotherapy in RCC: An Overview of Key New Data From ASCO, Part 2](#)
565. [Immunotherapy in RCC: An Overview of Key New Data From ASCO, Part 1](#)
566. [Adding Anthracyclines to the Adjuvant Treatment of Breast Cancer: Data Review and Practical Implications](#)
567. [New Data Review of CDK Inhibitors](#)
568. [CDK Inhibitors: Comparative Efficacy](#)
569. [HER2+ Cancer Treatment: Resistance, Immunologic Implications, and Biosimilars](#)
570. [5-Year Extended Adjuvant Aromatase Inhibition](#)
571. [Implications for Treatment of Estrogen Receptor Mutations](#)
572. [Neoadjuvant Breast Cancer Treatment: A Review of New Data](#)
573. [Some Key Take-Aways in Breast Cancer From ASCO 2016](#)
574. [New Data and New Drugs for Metastatic Breast Cancer: Recommendations by Patient Subtype](#)
575. [Key Breast Cancer Trials at ASCO 2016](#)
576. [New Data on Immunotherapy for Small-Cell Lung Cancer](#)
577. [Key Data From ASCO: Immunotherapy for Lung Cancer](#)
578. [Lung Cancer Overview From ASCO: Future Directions](#)
579. [Current Concepts in Anti-Angiogenic Therapy for Non–Small Cell Lung Cancer](#)
580. [Integrating Immunotherapy Into Small-Cell Lung Cancer Treatment: A Review of New Data](#)
581. [Practical Aspects of Immunotherapy for Thoracic Cancers](#)
582. [Role of Sipulucel T, Caccines, and Immunotherapy in Prostate Cancer](#)
583. [Predictive Biomarkers for Prostate Cancer Treatment Selection](#)
584. [Strategies for Micrometastatic RCC—Role of Adjuvant Therapy](#)
585. [Key New Trial Data in Neuro-Oncology](#)
586. [Metastatic Processes of Glioblastoma](#)
587. [Immunotherapy in Prostate Cancer: An Overview](#)
588. [New Immunotherapy Data in RCC](#)
589. [Hematology Practice Implications From ASCO: Chronic Lymphocytic Leukemia](#)
590. [ASCO 2016: Dr. Adam Brufsky on Treatment Developments in ER+ Breast Cancer](#)
591. [Personalized Medicine in Neuro-Oncology: Current Status](#)
592. [Evolving Role of PSA Screening in Prostate Cancer](#)
593. [Effect of Priming With Anti-Angiogenic Therapy](#)
594. [Effect of Decreased Screening on Prostate Cancer Patient Presentation](#)
595. [Generalized Inflammation and Brain Tumors: Is the Brain an 'Immunosanctuary'?](#)
596. [Future Directions for Targeted Therapies in Neuro-Oncology](#)
597. [High-Dose Chemotherapy and Stem Cell Transplantation for Glioblastoma](#)
598. [Clinical Implications of New Molecular Understanding in Glioblastoma](#)
599. [Tumor Treating Fields: Mechanism of Action and Clinical Implications](#)
600. [New Advances in Treating Glioblastoma in the Elderly](#)

601. [Whole Brain Radiation: Clinical Updates](#)
602. [Oligometastatic Disease: Surgical Extirpation and Treatment of Metastatic Lesions](#)
603. [Hormone Therapy After Salvage Radiation in the Post-Prostatectomy Setting](#)
604. [Personalized Medicine in Neuro-Oncology](#)
605. [Recent Trial Results: ECOG 2805 \(ASSURE\) and SWOG](#)
606. [Metastatic Bladder Cancer—Role of Checkpoint Inhibitors](#)
607. [Cabozantinib in RCC: Implications of Trial Data](#)
608. [Key Trial Data for Immune Checkpoint Inhibitors in mRCC](#)
609. [Nivolumab: PD1 Positivity vis-a-vis Effectiveness in RCC](#)
610. [Radiation Therapy and Hypofractionation Schedules in Prostate Cancer](#)
611. [Review of Ongoing Clinical Trials in Bladder Cancer](#)
612. [Bladder Cancer: Immunotherapy for Metastatic Bladder CA](#)
613. [New Classification Scheme for Low Grade Gliomas: Clinical Implications](#)
614. [Current Practice Implications of Tumor Treating Fields in Glioblastoma](#)
615. [SNO Practice Changers: Is There a Survival Advantage in Adding Bevacizumab to Nitrosoureas?](#)
616. [CATNON Trial: Implications for the Treatment of Intermediate Gliomas](#)
617. [EF-14 Trial Update: Tumor Treating Fields Show QoL Improvements in Addition to OS, PFS Benefits in Glioblastoma](#)
618. [EORTC Trial Results: Combining Bevacizumab With Lomustine](#)